Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Ramucirumab (anti-VEGFR2), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to VEGFR2, >95%, high purity, Human IgG1, Antibody of kinase insert domain receptor

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Features and benefits
  • Host species: Human
  • Species reactivity(Reacts with): Cynomolgus monkey,Human
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
Item Number
R411995
Grouped product items
SKUSizeAvailabilityPrice Qty
R411995-100μg
100μg
In stock
$39.90
R411995-1mg
1mg
In stock
$159.90
R411995-5mg
5mg
In stock
$664.90
R411995-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,196.90
Add to Wish List Compare
Bulk Order  DATASHEET

Purity>95% (SDS-PAGE&SEC); Endotoxin Level < 0.01EU/μg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series
Click to view target information: KDR
Accession#:P35968 Gene ID:3791 KDR kinase insert domain receptor Antibody Protein Tyrosine Kinase/RTK VEGFR VEGFR2

Basic Description

Product NameRamucirumab (anti-VEGFR2), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to VEGFR2, >95%, high purity, Human IgG1
SynonymsEC 2.7.10.1 | Fetal liver kinase 1 | FLK-1 | KDR | Kinase insert domain receptor | Protein-tyrosine kinase receptor flk-1 | VEGFR-2
Specifications & PurityExactAb™, Validated, Carrier Free, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Host speciesHuman
SpecificityVEGFR2
ApplicationELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Recombinant, Validated
Action TypeINHIBITOR
Mechanism of actionAntibody of kinase insert domain receptor
Product Description

Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. It is also an angiogenesis inhibitor.
Purity>95% (SDS-PAGE&SEC)
Endotoxin Level< 0.01EU/μg

Product Properties

Antibody TypePrimary antibody
ClonalityRecombinant
IsotypeHuman IgG1
Light Chain Typekappa
SDS-PAGE26.5 kDa (Light Chain) & 50.5 kDa (Heavy Chain), under reducing conditions; 176.7 kDa, under non-reducing conditions
Purification MethodProtein A purified
Purity>95%
SourceCHO supernatant
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS947687-13-0

Images

Ramucirumab (anti-VEGFR2) (R411995) - Flow Cytometry
Flow Cytometry analysis of HUVEC cells labelling VEGFR2 (red) with Ramucirumab (anti-VEGFR2) (R411995). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Ramucirumab (anti-VEGFR2) (R411995) - SEC
The purity of Ramucirumab (anti-VEGFR2) (R411995) is more than 95% verified by HPLC.

Associated Targets(Human)

KDR Tclin Vascular endothelial growth factor receptor 2 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
KDR Tclin Vascular endothelial growth factor receptor 2 (20924 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin VEGF-receptor 2 and Fibroblast growth factor receptor 2 (15 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin VEGF-receptor 2 and Fibroblast growth factor receptor 1 (50 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (14 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin TEL/KDR (9 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0303069Certificate of AnalysisMar 08, 2024 R411995
ZJ24F0303068Certificate of AnalysisMar 08, 2024 R411995
ZJ24F0303067Certificate of AnalysisMar 08, 2024 R411995

Related Documents

 SDS

 Specification Sheet

References

1. Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z.  (2002)  Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy..  Int J Cancer,  97  (3): (393-9).  [PMID:11774295] [10.1021/op500134e]
2. Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z.  (2003)  Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity..  J Biol Chem,  278  (44): (43496-507).  [PMID:12917408] [10.1021/op500134e]
3. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY et al..  (2019)  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial..  Lancet Oncol,  20  (2): (282-296).  [PMID:30665869] [10.1021/op500134e]
4. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO..  (2002)  Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors..  J Med Chem,  45  (6): (1300-1312).  [PMID:11881999] [10.1021/jm011022e]
5. Trejo A, Arzeno H, Browner M, Chanda S, Cheng S, Comer DD, Dalrymple SA, Dunten P, Lafargue J, Lovejoy B, Freire-Moar J, Lim J, Mcintosh J, Miller J, Papp E, Reuter D, Roberts R, Sanpablo F, Saunders J, Song K, Villasenor A, Warren SD, Welch M, Weller P, Whiteley PE, Zeng L, Goldstein DM..  (2003)  Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase..  J Med Chem,  46  (22): (4702-4713).  [PMID:14561090] [10.1021/jm0301787]
6. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S et al..  (2012)  7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes..  J Med Chem,  55  (1): (403-13).  [PMID:22136433] [10.1021/op500134e]
7. Soth M, Hermann JC, Yee C, Alam M, Barnett JW, Berry P, Browner MF, Frank K, Frauchiger S, Harris S et al..  (2013)  3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models..  J Med Chem,  56  (1): (345-56).  [PMID:23214979] [10.1021/op500134e]
8. McHardy T, Caldwell JJ, Cheung KM, Hunter LJ, Taylor K, Rowlands M, Ruddle R, Henley A, de Haven Brandon A, Valenti M et al..  (2010)  Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)..  J Med Chem,  53  (5): (2239-49).  [PMID:20151677] [10.1021/op500134e]
9. Kopecky DJ, Hao X, Chen Y, Fu J, Jiao X, Jaen JC, Cardozo MG, Liu J, Wang Z, Walker NP et al..  (2008)  Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors..  Bioorg Med Chem Lett,  18  (24): (6352-6).  [PMID:18993068] [10.1021/op500134e]
10. McTigue MA, Wickersham JA, Pinko C, Showalter RE, Parast CV, Tempczyk-Russell A, Gehring MR, Mroczkowski B, Kan CC, Villafranca JE et al..  (1999)  Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis..  Structure,  7  (3): (319-30).  [PMID:10368301] [10.1021/op500134e]
11. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al..  (2004)  The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)..  Genome Res,  14  (10B): (2121-7).  [PMID:15489334] [10.1021/op500134e]
12. Kubo K, Shimizu T, Ohyama S, Murooka H, Iwai A, Nakamura K, Hasegawa K, Kobayashi Y, Takahashi N, Takahashi K et al..  (2005)  Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas..  J Med Chem,  48  (5): (1359-66).  [PMID:15743179] [10.1021/op500134e]
13. Zhou W, Hur W, McDermott U, Dutt A, Xian W, Ficarro SB, Zhang J, Sharma SV, Brugge J, Meyerson M et al..  (2010)  A structure-guided approach to creating covalent FGFR inhibitors..  Chem Biol,  17  (3): (285-95).  [PMID:20338520] [10.1021/op500134e]
14. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D.  (2011)  Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity..  Int J Cancer,  129  (1): (245-55).  [PMID:21170960] [10.1021/op500134e]
15. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B et al..  (2011)  Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth..  Mol Cancer Ther,  10  (12): (2298-308).  [PMID:21926191] [10.1021/op500134e]
16. Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P et al..  (2006)  Allosteric inhibitors of Bcr-abl-dependent cell proliferation..  Nat Chem Biol,  2  (2): (95-102).  [PMID:16415863] [10.1021/op500134e]
17. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al..  (2007)  Patterns of somatic mutation in human cancer genomes..  Nature,  446  (7132): (153-8).  [PMID:17344846] [10.1021/op500134e]
18. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X et al..  (2003)  Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase..  J Med Chem,  46  (7): (1116-9).  [PMID:12646019] [10.1021/op500134e]
19. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM et al..  (2004)  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays..  J Med Chem,  47  (27): (6658-61).  [PMID:15615512] [10.1021/op500134e]
20. Gangjee A, Zhao Y, Ihnat MA, Thorpe JE, Bailey-Downs LC, Kisliuk RL.  (2012)  Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents..  Bioorg Med Chem,  20  (14): (4217-25).  [PMID:22739090] [10.1021/op500134e]
21. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS et al..  (2006)  Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor..  Mol Cancer Ther,  5  (4): (995-1006).  [PMID:16648571] [10.1021/op500134e]
22. Manley PW, Furet P, Bold G, Brüggen J, Mestan J, Meyer T, Schnell CR, Wood J, Haberey M, Huth A et al..  (2002)  Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors..  J Med Chem,  45  (26): (5687-93).  [PMID:12477352] [10.1021/op500134e]
23. Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Brüggen J, Buchdunger E, Cozens R et al..  (2000)  New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis..  J Med Chem,  43  (12): (2310-23).  [PMID:10882357] [10.1021/op500134e]
24. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J et al..  (2004)  AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity..  Cancer Res,  64  (14): (4931-41).  [PMID:15256466] [10.1021/op500134e]
25. Zhou Y, Chen Y, Tong L, Xie H, Wen W, Zhang J, Xi Y, Shen Y, Geng M, Wang Y et al..  (2012)  AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR..  J Cell Mol Med,  16  (10): (2321-30).  [PMID:22304225] [10.1021/op500134e]
26. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A et al..  (2006)  N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor..  J Med Chem,  49  (22): (6465-88).  [PMID:17064066] [10.1021/op500134e]
27. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J et al..  (2007)  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK..  Proc Natl Acad Sci USA,  104  (1): (270-5).  [PMID:17185414] [10.1021/op500134e]
28. Lin R, Connolly PJ, Huang S, Wetter SK, Lu Y, Murray WV, Emanuel SL, Gruninger RH, Fuentes-Pesquera AR, Rugg CA et al..  (2005)  1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities..  J Med Chem,  48  (13): (4208-11).  [PMID:15974571] [10.1021/op500134e]
29. Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ.  (2007)  Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one..  J Biol Chem,  282  (33): (24463-70).  [PMID:17562705] [10.1021/op500134e]
30. Zhang P, Hu HR, Huang ZH, Lei JY, Chu Y, Ye DY.  (2012)  Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening..  Bioorg Med Chem Lett,  22  (23): (7232-6).  [PMID:23099099] [10.1021/op500134e]
31. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al..  (2006)  Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity..  J Med Chem,  49  (12): (3563-80).  [PMID:16759099] [10.1021/op500134e]
32. Sun L, Tran N, Liang C, Hubbard S, Tang F, Lipson K, Schreck R, Zhou Y, McMahon G, Tang C.  (2000)  Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases..  J Med Chem,  43  (14): (2655-63).  [PMID:10893303] [10.1021/op500134e]
33. Sun L, Tran N, Liang C, Tang F, Rice A, Schreck R, Waltz K, Shawver LK, McMahon G, Tang C.  (1999)  Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases..  J Med Chem,  42  (25): (5120-30).  [PMID:10602697] [10.1021/op500134e]
34. Aston NM, Bamborough P, Buckton JB, Edwards CD, Holmes DS, Jones KL, Patel VK, Smee PA, Somers DO, Vitulli G et al..  (2009)  p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression..  J Med Chem,  52  (20): (6257-69).  [PMID:19772287] [10.1021/op500134e]
35. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H et al..  (2011)  Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase..  J Med Chem,  54  (20): (7066-83).  [PMID:21936542] [10.1021/op500134e]
36. Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L et al..  (2012)  Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E..  J Med Chem,  55  (3): (1082-105).  [PMID:22168626] [10.1021/op500134e]
37. Currie KS, Kropf JE, Lee T, Blomgren P, Xu J, Zhao Z, Gallion S, Whitney JA, Maclin D, Lansdon EB et al..  (2014)  Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase..  J Med Chem,  57  (9): (3856-73).  [PMID:24779514] [10.1021/op500134e]
38. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW et al..  (2013)  Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design..  ACS Med Chem Lett,  4  (1): (91-7).  [PMID:24900568] [10.1021/op500134e]
39. Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P et al..  (2006)  1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile..  J Med Chem,  49  (24): (7247-51).  [PMID:17125279] [10.1021/op500134e]
40. Nakagawa T, Tohyama O, Yamaguchi A, Matsushima T, Takahashi K, Funasaka S, Shirotori S, Asada M, Obaishi H.  (2010)  E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models..  Cancer Sci,  101  (1): (210-5).  [PMID:19832844] [10.1021/op500134e]
41. Engler TA, Henry JR, Malhotra S, Cunningham B, Furness K, Brozinick J, Burkholder TP, Clay MP, Clayton J, Diefenbacher C et al..  (2004)  Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3..  J Med Chem,  47  (16): (3934-7).  [PMID:15267232] [10.1021/op500134e]
42. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H et al..  (2010)  MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor..  Cancer Res,  70  (4): (1524-33).  [PMID:20145145] [10.1021/op500134e]
43. Machrouhi F, Ouhamou N, Laderoute K, Calaoagan J, Bukhtiyarova M, Ehrlich PJ, Klon AE.  (2010)  The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity..  Bioorg Med Chem Lett,  20  (22): (6394-9).  [PMID:20932747] [10.1021/op500134e]
44. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA.  (2008)  Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases..  Nat Chem Biol,  4  (11): (691-9).  [PMID:18849971] [10.1021/op500134e]
45. Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H, Zhu D, Biroc SL, Alicke B, Bryant J, Yuan S et al..  (2005)  Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1..  J Biol Chem,  280  (20): (19867-74).  [PMID:15772071] [10.1021/op500134e]
46. Medina JR, Becker CJ, Blackledge CW, Duquenne C, Feng Y, Grant SW, Heerding D, Li WH, Miller WH, Romeril SP et al..  (2011)  Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors..  J Med Chem,  54  (6): (1871-95).  [PMID:21341675] [10.1021/op500134e]
47. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al..  (2009)  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)..  Blood,  114  (14): (2984-92).  [PMID:19654408] [10.1021/op500134e]
48. Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM et al..  (2005)  Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580..  Proc Natl Acad Sci USA,  102  (44): (16078-83).  [PMID:16249345] [10.1021/op500134e]
49. Sampson PB, Liu Y, Patel NK, Feher M, Forrest B, Li SW, Edwards L, Laufer R, Lang Y, Ban F et al..  (2015)  The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents..  J Med Chem,  58  (1): (130-46).  [PMID:24867403] [10.1021/op500134e]
50. Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R et al..  (2007)  The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells..  Cancer Res,  67  (14): (6956-64).  [PMID:17638907] [10.1021/op500134e]
51. Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M, Yoneda T, Isoe T.  (2006)  A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model..  Mol Cancer Ther,  5  (11): (2634-43).  [PMID:17121910] [10.1021/op500134e]
52. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ et al..  (2007)  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase..  Proc Natl Acad Sci USA,  104  (10): (4106-11).  [PMID:17360485] [10.1021/op500134e]
53. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB et al..  (2003)  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship..  Clin Cancer Res,  9  (1): (327-37).  [PMID:12538485] [10.1021/op500134e]
54. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK.  (2005)  CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma..  Blood,  105  (7): (2941-8).  [PMID:15598814] [10.1021/op500134e]
55. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M et al..  (2004)  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis..  Cancer Res,  64  (19): (7099-109).  [PMID:15466206] [10.1021/op500134e]
56. Zhao G, Li WY, Chen D, Henry JR, Li HY, Chen Z, Zia-Ebrahimi M, Bloem L, Zhai Y, Huss K et al..  (2011)  A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models..  Mol Cancer Ther,  10  (11): (2200-10).  [PMID:21900693] [10.1021/op500134e]
57. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR.  (2013)  Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe..  Bioorg Med Chem Lett,  23  (11): (3248-52).  [PMID:23639540] [10.1021/op500134e]
58. Hall MD, Salam NK, Hellawell JL, Fales HM, Kensler CB, Ludwig JA, Szakács G, Hibbs DE, Gottesman MM.  (2009)  Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells..  J Med Chem,  52  (10): (3191-204).  [PMID:19397322] [10.1021/op500134e]
59. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C.  (2009)  Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4)..  J Med Chem,  52  (20): (6433-46).  [PMID:19788238] [10.1021/op500134e]
60. Pandey A, Volkots DL, Seroogy JM, Rose JW, Yu JC, Lambing JL, Hutchaleelaha A, Hollenbach SJ, Abe K, Giese NA et al..  (2002)  Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family..  J Med Chem,  45  (17): (3772-93).  [PMID:12166950] [10.1021/op500134e]
61. Millan DS, Bunnage ME, Burrows JL, Butcher KJ, Dodd PG, Evans TJ, Fairman DA, Hughes SJ, Kilty IC, Lemaitre A et al..  (2011)  Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease..  J Med Chem,  54  (22): (7797-814).  [PMID:21888439] [10.1021/op500134e]
62. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K et al..  (2012)  Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent..  J Med Chem,  55  (2): (903-13).  [PMID:22148921] [10.1021/op500134e]
63. Weïwer M, Spoonamore J, Wei J, Guichard B, Ross NT, Masson K, Silkworth W, Dandapani S, Palmer M, Scherer CA et al..  (2012)  A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells..  ACS Med Chem Lett,  3  (12): (1034-1038).  [PMID:23256033] [10.1021/op500134e]
64. Burgess A, Wigan M, Giles N, Depinto W, Gillespie P, Stevens F, Gabrielli B.  (2006)  Inhibition of S/G2 phase CDK4 reduces mitotic fidelity..  J Biol Chem,  281  (15): (9987-95).  [PMID:16476733] [10.1021/op500134e]
65. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM.  (2009)  Inhibitor hijacking of Akt activation..  Nat Chem Biol,  5  (7): (484-93).  [PMID:19465931] [10.1021/op500134e]
66. Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO et al..  (1999)  Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors..  J Med Chem,  42  (26): (5369-89).  [PMID:10639280] [10.1021/op500134e]
67. Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M et al..  (2015)  Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy..  J Med Chem,  58  (17): (6875-98).  [PMID:26222319] [10.1021/op500134e]
68. Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C.  (2010)  Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer..  J Med Chem,  53  (5): (2000-9).  [PMID:20143778] [10.1021/op500134e]
69. Bode CM, Boezio AA, Albrecht BK, Bellon SF, Berry L, Broome MA, Choquette D, Dussault I, Lewis RT, Lin MH et al..  (2012)  Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors..  Bioorg Med Chem Lett,  22  (12): (4089-93).  [PMID:22595176] [10.1021/op500134e]
70. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI et al..  (2015)  Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor..  N Engl J Med,  373  (5): (428-37).  [PMID:26222558] [10.1021/op500134e]
71. Haile PA, Votta BJ, Marquis RW, Bury MJ, Mehlmann JF, Singhaus Jr R, Charnley AK, Lakdawala AS, Convery MA, Lipshutz DB et al..  (2016)  The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase..  J Med Chem,  59  (10): (4867-80).  [PMID:27109867] [10.1021/op500134e]
72. Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, Ewing NP, Ford PJ, Germann UA, Green J et al..  (2009)  Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control..  J Med Chem,  52  (20): (6362-8).  [PMID:19827834] [10.1021/op500134e]
73. Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J et al..  (2011)  Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis..  Bioorg Med Chem Lett,  21  (21): (6258-63).  [PMID:21958547] [10.1021/op500134e]
74. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al..  (2015)  Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders..  J Med Chem,  58  (23): (9154-70).  [PMID:26509640] [10.1021/op500134e]
75. Lam B, Arikawa Y, Cramlett J, Dong Q, de Jong R, Feher V, Grimshaw CE, Farrell PJ, Hoffman ID, Jennings A et al..  (2016)  Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)..  Bioorg Med Chem Lett,  26  (24): (5947-5950).  [PMID:27839918] [10.1021/op500134e]
76. Huang Z, Li H, Zhang Q, Lu F, Hong M, Zhang Z, Guo X, Zhu Y, Li S, Liu H.  (2017)  Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis..  ACS Med Chem Lett,  8  (11): (1142-1147).  [PMID:29152045] [10.1021/op500134e]
77. Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G et al..  (2017)  Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors..  Bioorg Med Chem,  25  (4): (1320-1328).  [PMID:28038940] [10.1021/op500134e]
78. Brameld KA, Owens TD, Verner E, Venetsanakos E, Bradshaw JM, Phan VT, Tam D, Leung K, Shu J, LaStant J et al..  (2017)  Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors..  J Med Chem,  60  (15): (6516-6527).  [PMID:28665128] [10.1021/op500134e]
79. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al..  (2015)  Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies..  J Med Chem,  58  (21): (8373-86).  [PMID:26505898] [10.1021/op500134e]
80. Lucas MC, Goldstein DM, Hermann JC, Kuglstatter A, Liu W, Luk KC, Padilla F, Slade M, Villaseñor AG, Wanner J et al..  (2012)  Rational design of highly selective spleen tyrosine kinase inhibitors..  J Med Chem,  55  (23): (10414-23).  [PMID:23151054] [10.1021/op500134e]
81. Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH et al..  (2012)  Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families..  J Pharmacol Exp Ther,  343  (3): (617-27).  [PMID:22935731] [10.1021/op500134e]
82. Patwardhan PP, Ivy KS, Musi E, de Stanchina E, Schwartz GK.  (2016)  Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma..  Oncotarget,  7  (4): (4093-109).  [PMID:26675259] [10.1021/op500134e]
83. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y et al..  (2015)  Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12)..  J Med Chem,  58  (20): (8182-99).  [PMID:26431428] [10.1021/op500134e]
84. Vazquez ML, Kaila N, Strohbach JW, Trzupek JD, Brown MF, Flanagan ME, Mitton-Fry MJ, Johnson TA, TenBrink RE, Arnold EP et al..  (2018)  Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases..  J Med Chem,  61  (3): (1130-1152).  [PMID:29298069] [10.1021/op500134e]
85. Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D et al..  (2018)  Precision Targeted Therapy with BLU-667 for RET-Driven Cancers..  Cancer Discov,  8  (7): (836-849).  [PMID:29657135] [10.1021/op500134e]
86. Heffron TP, Ndubaku CO, Salphati L, Alicke B, Cheong J, Drobnick J, Edgar K, Gould SE, Lee LB, Lesnick JD et al..  (2016)  Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR..  ACS Med Chem Lett,  7  (4): (351-6).  [PMID:27096040] [10.1021/op500134e]
87. Reich SH, Sprengeler PA, Chiang GG, Appleman JR, Chen J, Clarine J, Eam B, Ernst JT, Han Q, Goel VK et al..  (2018)  Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition..  J Med Chem,  61  (8): (3516-3540).  [PMID:29526098] [10.1021/op500134e]
88. You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, McDonald DM.  (2011)  VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer..  Cancer Res,  71  (14): (4758-68).  [PMID:21613405] [10.1021/op500134e]
89. Fensome A, Ambler CM, Arnold E, Banker ME, Brown MF, Chrencik J, Clark JD, Dowty ME, Efremov IV, Flick A et al..  (2018)  Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)..  J Med Chem,  61  (19): (8597-8612).  [PMID:30113844] [10.1021/op500134e]
90. Zhang J, Jiang X, Jiang Y, Guo M, Zhang S, Li J, He J, Liu J, Wang J, Ouyang L.  (2016)  Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs..  Eur J Med Chem,  108  (13): (495-504).  [PMID:26717201] [10.1021/op500134e]
91. Zhou Y, Shan S, Li ZB, Xin LJ, Pan DS, Yang QJ, Liu YP, Yue XP, Liu XR, Gao JZ et al..  (2017)  CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency..  Cancer Sci,  108  (3): (469-477).  [PMID:28004478] [10.1021/op500134e]
92. Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A, Winfield N, Ellard K, Aqil R, Lynch R, Chapman C et al..  (2010)  Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction..  J Med Chem,  53  (5): (2215-26).  [PMID:20151671] [10.1021/op500134e]
93. Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA.  (2002)  Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors..  Blood,  100  (2): (585-93).  [PMID:12091352] [10.1021/op500134e]
94. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H.  (2018)  A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy..  Eur J Med Chem,  144  (13): (1-28).  [PMID:29247857] [10.1021/op500134e]
95. Qing-Shan Li,Xian-Hai Lv,Yan-Bin Zhang,Jing-Jun Dong,Wen-Ping Zhou,Yang Yang,Hai-Liang Zhu.  (2012-10-03)  Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents..  Bioorganic & medicinal chemistry letters,  22  ((21)): (6596-6601).  [PMID:23025996]
96. Seunghee Hong,Jinhee Kim,Sun-Mi Yun,Hyunseung Lee,Yoonsu Park,Soon-Sun Hong,Sungwoo Hong.  (2013-04-23)  Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant..  Journal of medicinal chemistry,  56  ((9)): (3531-3545).  [PMID:23600806]
97. Sung Hee Hwang, Aaron T Wecksler, Guodong Zhang, Christophe Morisseau, Long V Nguyen, Samuel H Fu, Bruce D Hammock,.  (2013-06-04)  Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors..  Bioorganic & medicinal chemistry letters,  23  ((13)): ( 3732-3737 ).  [PMID:23726028]
98. Ajit Dhananjay Jagtap,Pei-Teh Chang,Jia-Rong Liu,Hsiao-Chun Wang,Nagendra B Kondekar,Li-Jiuan Shen,Hsiang-Wen Tseng,Grace Shiahuy Chen,Ji-Wang Chern.  (2014-08-05)  Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia..  European journal of medicinal chemistry,  85  (268-288).  [PMID:25089810]
99. Emily J Hanan,Charles Eigenbrot,Marian C Bryan,Daniel J Burdick,Bryan K Chan,Yuan Chen,Jennafer Dotson,Robert A Heald,Philip S Jackson,Hank La,Michael D Lainchbury,Shiva Malek,Hans E Purkey,Gabriele Schaefer,Stephen Schmidt,Eileen M Seward,Steve Sideris,Christine Tam,Shumei Wang,Siew Kuen Yeap,Ivana Yen,Jianping Yin,Christine Yu,Inna Zilberleyb,Timothy P Heffron.  (2014-11-11)  Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation..  Journal of medicinal chemistry,  57  ((23)): (10176-10191).  [PMID:25383627]
100. Ingrid Nilsson,Fuad Bahram,Xiujuan Li,Laura Gualandi,Sina Koch,Malin Jarvius,Ola Söderberg,Andrey Anisimov,Ivana Kholová,Bronislaw Pytowski,Megan Baldwin,Seppo Ylä-Herttuala,Kari Alitalo,Johan Kreuger,Lena Claesson-Welsh.  (2010-03-13)  VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts..  The EMBO journal,  29  ((8)): (1377-1388).  [PMID:20224550]
101. Bing Yu,Li-da Tang,Yi-Liang Li,Shu-Hui Song,Xiao-Liang Ji,Mu-Sen Lin,Chun-Fu Wu.  (2011-12-16)  Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase..  Bioorganic & medicinal chemistry letters,  22  ((1)): (110-114).  [PMID:22169262]
102. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G..  (2004)  Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis..  Bioorg Med Chem Lett,  14  (13): (3595-3599).  [PMID:15177482] [10.1016/j.bmcl.2004.03.106]
103. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G..  (2004)  SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity..  Bioorg Med Chem Lett,  14  (13): (3601-3605).  [PMID:15177483] [10.1016/j.bmcl.2004.03.111]
104. Pevarello P, Brasca MG, Amici R, Orsini P, Traquandi G, Corti L, Piutti C, Sansonna P, Villa M, Pierce BS, Pulici M, Giordano P, Martina K, Fritzen EL, Nugent RA, Casale E, Cameron A, Ciomei M, Roletto F, Isacchi A, Fogliatto G, Pesenti E, Pastori W, Marsiglio A, Leach KL, Clare PM, Fiorentini F, Varasi M, Vulpetti A, Warpehoski MA..  (2004)  3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding..  J Med Chem,  47  (13): (3367-3380).  [PMID:15189033] [10.1021/jm031145u]
105. Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Fura A, Kamath A, Vyas V, Tokarski JS, Barrish JC, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS..  (2005)  Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors..  J Med Chem,  48  (12): (3991-4008).  [PMID:15943473] [10.1021/jm0501275]
106. Kuo GH, Prouty C, Wang A, Emanuel S, Deangelis A, Zhang Y, Song F, Beall L, Connolly PJ, Karnachi P, Chen X, Gruninger RH, Sechler J, Fuentes-Pesquera A, Middleton SA, Jolliffe L, Murray WV..  (2005)  Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors..  J Med Chem,  48  (15): (4892-4909).  [PMID:16033269] [10.1021/jm058205b]
107. Bouérat L, Fensholdt J, Liang X, Havez S, Nielsen SF, Hansen JR, Bolvig S, Andersson C..  (2005)  Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis..  J Med Chem,  48  (17): (5412-5414).  [PMID:16107139] [10.1021/jm0504151]
108. Kuo GH, Wang A, Emanuel S, Deangelis A, Zhang R, Connolly PJ, Murray WV, Gruninger RH, Sechler J, Fuentes-Pesquera A, Johnson D, Middleton SA, Jolliffe L, Chen X..  (2005)  Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors..  J Med Chem,  48  (6): (1886-1900).  [PMID:15771433] [10.1021/jm040099a]
109. Dai Y, Guo Y, Frey RR, Ji Z, Curtin ML, Ahmed AA, Albert DH, Arnold L, Arries SS, Barlozzari T, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Pease LJ, Stewart KD, Stoll VS, Tapang P, Wishart N, Davidsen SK, Michaelides MR..  (2005)  Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors..  J Med Chem,  48  (19): (6066-6083).  [PMID:16162008] [10.1021/jm050458h]
110. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Neumann U, Rucklin G..  (2006)  Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity..  Bioorg Med Chem Lett,  16  (2): (262-266).  [PMID:16249085] [10.1016/j.bmcl.2005.10.015]
111. McDermott LA, Higgins B, Simcox M, Luk KC, Nevins T, Kolinsky K, Smith M, Yang H, Li JK, Chen Y, Ke J, Mallalieu N, Egan T, Kolis S, Railkar A, Gerber L, Liu JJ, Konzelmann F, Zhang Z, Flynn T, Morales O, Chen Y..  (2006)  Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis..  Bioorg Med Chem Lett,  16  (7): (1950-1953).  [PMID:16460940] [10.1016/j.bmcl.2005.12.092]
112. Zhao H, Serby MD, Xin Z, Szczepankiewicz BG, Liu M, Kosogof C, Liu B, Nelson LT, Johnson EF, Wang S, Pederson T, Gum RJ, Clampit JE, Haasch DL, Abad-Zapatero C, Fry EH, Rondinone C, Trevillyan JM, Sham HL, Liu G..  (2006)  Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors..  J Med Chem,  49  (15): (4455-4458).  [PMID:16854050] [10.1021/jm060465l]
113. Borzilleri RM, Bhide RS, Barrish JC, D'Arienzo CJ, Derbin GM, Fargnoli J, Hunt JT, Jeyaseelan R, Kamath A, Kukral DW, Marathe P, Mortillo S, Qian L, Tokarski JS, Wautlet BS, Zheng X, Lombardo LJ..  (2006)  Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2..  J Med Chem,  49  (13): (3766-3769).  [PMID:16789733] [10.1021/jm060347y]
114. DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan JL, Buckner WH, Cee VJ, Chai L, Deak HL, Epstein LF, Faust T, Gallant P, Geuns-Meyer SD, Gore A, Gu Y, Henkle B, Hodous BL, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, Masse CE, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, White RD, Zhao H, Zhu L, Zhu X..  (2006)  Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity..  J Med Chem,  49  (19): (5671-5686).  [PMID:16970394] [10.1021/jm0605482]
115. Cee VJ, Albrecht BK, Geuns-Meyer S, Hughes P, Bellon S, Bready J, Caenepeel S, Chaffee SC, Coxon A, Emery M, Fretland J, Gallant P, Gu Y, Hodous BL, Hoffman D, Johnson RE, Kendall R, Kim JL, Long AM, McGowan D, Morrison M, Olivieri PR, Patel VF, Polverino A, Powers D, Rose P, Wang L, Zhao H..  (2007)  Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase..  J Med Chem,  50  (4): (627-640).  [PMID:17253679] [10.1021/jm061112p]
116. Aronov AM, Baker C, Bemis GW, Cao J, Chen G, Ford PJ, Germann UA, Green J, Hale MR, Jacobs M, Janetka JW, Maltais F, Martinez-Botella G, Namchuk MN, Straub J, Tang Q, Xie X..  (2007)  Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors..  J Med Chem,  50  (6): (1280-1287).  [PMID:17300186] [10.1021/jm061381f]
117. Leftheris K, Ahmed G, Chan R, Dyckman AJ, Hussain Z, Ho K, Hynes J, Letourneau J, Li W, Lin S, Metzger A, Moriarty KJ, Riviello C, Shimshock Y, Wen J, Wityak J, Wrobleski ST, Wu H, Wu J, Desai M, Gillooly KM, Lin TH, Loo D, McIntyre KW, Pitt S, Shen DR, Shuster DJ, Zhang R, Diller D, Doweyko A, Sack J, Baldwin J, Barrish J, Dodd J, Henderson I, Kanner S, Schieven GL, Webb M..  (2004)  The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase..  J Med Chem,  47  (25): (6283-6291).  [PMID:15566298] [10.1021/jm049521d]
118. Mukaiyama H, Nishimura T, Kobayashi S, Ozawa T, Kamada N, Komatsu Y, Kikuchi S, Oonota H, Kusama H..  (2007)  Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke..  Bioorg Med Chem,  15  (2): (868-885).  [PMID:17095233] [10.1016/j.bmc.2006.10.041]
119. Dinges J, Albert DH, Arnold LD, Ashworth KL, Akritopoulou-Zanze I, Bousquet PF, Bouska JJ, Cunha GA, Davidsen SK, Diaz GJ, Djuric SW, Gasiecki AF, Gintant GA, Gracias VJ, Harris CM, Houseman KA, Hutchins CW, Johnson EF, Li H, Marcotte PA, Martin RL, Michaelides MR, Nyein M, Sowin TJ, Su Z, Tapang PH, Xia Z, Zhang HQ..  (2007)  1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel..  J Med Chem,  50  (9): (2011-2029).  [PMID:17425296] [10.1021/jm061223o]
120. Hughes TV, Emanuel SL, Beck AK, Wetter SK, Connolly PJ, Karnachi P, Reuman M, Seraj J, Fuentes-Pesquera AR, Gruninger RH, Middleton SA, Lin R, Davis JM, Moffat DF..  (2007)  4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation..  Bioorg Med Chem Lett,  17  (12): (3266-3270).  [PMID:17481894] [10.1016/j.bmcl.2007.04.021]
121. Potashman MH, Bready J, Coxon A, DeMelfi TM, DiPietro L, Doerr N, Elbaum D, Estrada J, Gallant P, Germain J, Gu Y, Harmange JC, Kaufman SA, Kendall R, Kim JL, Kumar GN, Long AM, Neervannan S, Patel VF, Polverino A, Rose P, Plas Sv, Whittington D, Zanon R, Zhao H..  (2007)  Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors..  J Med Chem,  50  (18): (4351-4373).  [PMID:17696416] [10.1021/jm070034i]
122. Graham Robinett R, Freemerman AJ, Skinner MA, Shewchuk L, Lackey K..  (2007)  The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors..  Bioorg Med Chem Lett,  17  (21): (5886-5893).  [PMID:17884497] [10.1016/j.bmcl.2007.07.104]
123. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M..  (2007)  Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice..  J Med Chem,  50  (23): (5579-5588).  [PMID:17929792] [10.1021/jm061449r]
124. Ji Z, Ahmed AA, Albert DH, Bouska JJ, Bousquet PF, Cunha GA, Diaz G, Glaser KB, Guo J, Harris CM, Li J, Marcotte PA, Moskey MD, Oie T, Pease L, Soni NB, Stewart KD, Davidsen SK, Michaelides MR..  (2008)  3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases..  J Med Chem,  51  (5): (1231-1241).  [PMID:18260617] [10.1021/jm701096v]
125. Martin MW, Newcomb J, Nunes JJ, Boucher C, Chai L, Epstein LF, Faust T, Flores S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Kim JL, Middleton S, Morgenstern K, Oliveira-dos-Santos A, Patel VF, Powers D, Rose P, Tudor Y, Turci SM, Welcher AA, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Ermann M, Johnston D, Saluste CG..  (2008)  Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity..  J Med Chem,  51  (6): (1637-1648).  [PMID:18278858] [10.1021/jm701095m]
126. Angell RM, Angell TD, Bamborough P, Brown D, Brown M, Buckton JB, Cockerill SG, Edwards CD, Jones KL, Longstaff T, Smee PA, Smith KJ, Somers DO, Walker AL, Willson M..  (2008)  Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR..  Bioorg Med Chem Lett,  18  (1): (324-328).  [PMID:17981461] [10.1016/j.bmcl.2007.10.043]
127. Cai ZW, Wei D, Borzilleri RM, Qian L, Kamath A, Mortillo S, Wautlet B, Henley BJ, Jeyaseelan R, Tokarski J, Hunt JT, Bhide RS, Fargnoli J, Lombardo LJ..  (2008)  Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors..  Bioorg Med Chem Lett,  18  (4): (1354-1358).  [PMID:18221875] [10.1016/j.bmcl.2008.01.012]
128. Palanki MS, Akiyama H, Campochiaro P, Cao J, Chow CP, Dellamary L, Doukas J, Fine R, Gritzen C, Hood JD, Hu S, Kachi S, Kang X, Klebansky B, Kousba A, Lohse D, Mak CC, Martin M, McPherson A, Pathak VP, Renick J, Soll R, Umeda N, Yee S, Yokoi K, Zeng B, Zhu H, Noronha G..  (2008)  Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration..  J Med Chem,  51  (6): (1546-1559).  [PMID:18311895] [10.1021/jm7011276]
129. La DS, Belzile J, Bready JV, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn JC, Flynn SR, Graceffa RF, Harriman SP, Larrow JF, Long AM, Martin MW, Morrison MJ, Patel VF, Roveto PM, Wang L, Weiss MM, Whittington DA, Teffera Y, Zhao Z, Polverino AJ, Harmange JC..  (2008)  Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis..  J Med Chem,  51  (6): (1695-1705).  [PMID:18311900] [10.1021/jm701129j]
130. DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Chai L, Chaffee SC, Deak HL, Epstein LF, Faust T, Gallant P, Gore A, Gu Y, Henkle B, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, Zhao H, Zhu L, Zhu X..  (2008)  Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation..  J Med Chem,  51  (6): (1681-1694).  [PMID:18321037] [10.1021/jm7010996]
131. Weiss MM, Harmange JC, Polverino AJ, Bauer D, Berry L, Berry V, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Whittington DA, Zanon R..  (2008)  Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors..  J Med Chem,  51  (6): (1668-1680).  [PMID:18324759] [10.1021/jm701098w]
132. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J..  (2007)  Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling..  Proc Natl Acad Sci U S A,  104  (50): (19936-19941).  [PMID:18077425] [10.1073/pnas.0707498104]
133. Udugamasooriya DG, Ritchie C, Brekken RA, Kodadek T..  (2008)  A peptoid antagonist of VEGF receptor 2 recognizes a 'hotspot' in the extracellular domain distinct from the hormone-binding site..  Bioorg Med Chem,  16  (12): (6338-6343).  [PMID:18501615] [10.1016/j.bmc.2008.05.015]
134. Rellos P, Ivins FJ, Baxter JE, Pike A, Nott TJ, Parkinson DM, Das S, Howell S, Fedorov O, Shen QY, Fry AM, Knapp S, Smerdon SJ..  (2007)  Structure and regulation of the human Nek2 centrosomal kinase..  J Biol Chem,  282  (9): (6833-6842).  [PMID:17197699] [10.1074/jbc.m609721200]
135. Kim KS, Zhang L, Schmidt R, Cai ZW, Wei D, Williams DK, Lombardo LJ, Trainor GL, Xie D, Zhang Y, An Y, Sack JS, Tokarski JS, Darienzo C, Kamath A, Marathe P, Zhang Y, Lippy J, Jeyaseelan R, Wautlet B, Henley B, Gullo-Brown J, Manne V, Hunt JT, Fargnoli J, Borzilleri RM..  (2008)  Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities..  J Med Chem,  51  (17): (5330-5341).  [PMID:18690676] [10.1021/jm800476q]
136. Liu L, Siegmund A, Xi N, Kaplan-Lefko P, Rex K, Chen A, Lin J, Moriguchi J, Berry L, Huang L, Teffera Y, Yang Y, Zhang Y, Bellon SF, Lee M, Shimanovich R, Bak A, Dominguez C, Norman MH, Harmange JC, Dussault I, Kim TS..  (2008)  Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)..  J Med Chem,  51  (13): (3688-3691).  [PMID:18553959] [10.1021/jm800401t]
137. Kunz RK, Rumfelt S, Chen N, Zhang D, Tasker AS, Bürli R, Hungate R, Yu V, Nguyen Y, Whittington DA, Meagher KL, Plant M, Tudor Y, Schrag M, Xu Y, Ng GY, Hu E..  (2008)  Discovery of amido-benzisoxazoles as potent c-Kit inhibitors..  Bioorg Med Chem Lett,  18  (18): (5115-5117).  [PMID:18723346] [10.1016/j.bmcl.2008.07.111]
138. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P..  (2008)  Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors..  J Med Chem,  51  (21): (6642-6645).  [PMID:18834107] [10.1021/jm800986w]
139. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD..  (2009)  Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases..  J Med Chem,  52  (1): (74-86).  [PMID:19072652] [10.1021/jm800937p]
140. D'Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I, Kim TS..  (2008)  Design, synthesis, and biological evaluation of potent c-Met inhibitors..  J Med Chem,  51  (18): (5766-5779).  [PMID:18763753] [10.1021/jm8006189]
141. Cole DC, Asselin M, Brennan A, Czerwinski R, Ellingboe JW, Fitz L, Greco R, Huang X, Joseph-McCarthy D, Kelly MF, Kirisits M, Lee J, Li Y, Morgan P, Stock JR, Tsao DH, Wissner A, Yang X, Chaudhary D..  (2008)  Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors..  J Med Chem,  51  (19): (5958-5963).  [PMID:18783200] [10.1021/jm800214a]
142. Peach ML, Tan N, Choyke SJ, Giubellino A, Athauda G, Burke TR, Nicklaus MC, Bottaro DP..  (2009)  Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening..  J Med Chem,  52  (4): (943-951).  [PMID:19199650] [10.1021/jm800791f]
143. Mahboobi S, Dove S, Sellmer A, Winkler M, Eichhorn E, Pongratz H, Ciossek T, Baer T, Maier T, Beckers T..  (2009)  Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases..  J Med Chem,  52  (8): (2265-2279).  [PMID:19301902] [10.1021/jm800988r]
144. Lee K, Kim J, Jeong KW, Lee KW, Lee Y, Song JY, Kim MS, Lee GS, Kim Y..  (2009)  Structure-based virtual screening of Src kinase inhibitors..  Bioorg Med Chem,  17  (8): (3152-3161).  [PMID:19321350] [10.1016/j.bmc.2009.02.054]
145. Udugamasooriya DG, Dunham G, Ritchie C, Brekken RA, Kodadek T..  (2008)  The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues..  Bioorg Med Chem Lett,  18  (22): (5892-5894).  [PMID:18653335] [10.1016/j.bmcl.2008.07.023]
146. Gopalsamy A, Ciszewski G, Hu Y, Lee F, Feldberg L, Frommer E, Kim S, Collins K, Wojciechowicz D, Mallon R..  (2009)  Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors..  Bioorg Med Chem Lett,  19  (10): (2735-2738).  [PMID:19362830] [10.1016/j.bmcl.2009.03.129]
147. Li R, Pourpak A, Morris SW..  (2009)  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach..  J Med Chem,  52  (16): (4981-5004).  [PMID:19610618] [10.1021/jm9002395]
148. Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, Han DK, Lee HS, Lee JY, Lee SH..  (2009)  Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor..  Bioorg Med Chem Lett,  19  (16): (4720-4723).  [PMID:19596575] [10.1016/j.bmcl.2009.06.066]
149. Cha MY, Lee KO, Kim JW, Lee CG, Song JY, Kim YH, Lee GS, Park SB, Kim MS..  (2009)  Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer..  J Med Chem,  52  (21): (6880-6888).  [PMID:19888761] [10.1021/jm901146p]
150. Li J, Kaoud TS, Laroche C, Dalby KN, Kerwin SM..  (2009)  Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles..  Bioorg Med Chem Lett,  19  (22): (6293-6297).  [PMID:19822424] [10.1016/j.bmcl.2009.09.094]
151. Shomin CD, Meyer SC, Ghosh I..  (2009)  Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling..  Bioorg Med Chem,  17  (17): (6196-6202).  [PMID:19674907] [10.1016/j.bmc.2009.07.056]
152. Gangjee A, Li W, Lin L, Zeng Y, Ihnat M, Warnke LA, Green DW, Cody V, Pace J, Queener SF..  (2009)  Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors..  Bioorg Med Chem,  17  (20): (7324-7336).  [PMID:19748785] [10.1016/j.bmc.2009.08.044]
153. Wee XK, Yeo WK, Zhang B, Tan VB, Lim KM, Tay TE, Go ML..  (2009)  Synthesis and evaluation of functionalized isoindigos as antiproliferative agents..  Bioorg Med Chem,  17  (21): (7562-7571).  [PMID:19783149] [10.1016/j.bmc.2009.09.008]
154. Egert-Schmidt AM, Dreher J, Dunkel U, Kohfeld S, Preu L, Weber H, Ehlert JE, Mutschler B, Totzke F, Schächtele C, Kubbutat MH, Baumann K, Kunick C..  (2010)  Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation..  J Med Chem,  53  (6): (2433-2442).  [PMID:20170163] [10.1021/jm901388c]
155. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD..  (2009)  Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors..  Bioorg Med Chem Lett,  19  (21): (6122-6126).  [PMID:19783434] [10.1016/j.bmcl.2009.09.010]
156. Gangjee A, Zaware N, Raghavan S, Ihnat M, Shenoy S, Kisliuk RL..  (2010)  Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents..  J Med Chem,  53  (4): (1563-1578).  [PMID:20092323] [10.1021/jm9011142]
157. Pettus LH, Wurz RP, Xu S, Herberich B, Henkle B, Liu Q, McBride HJ, Mu S, Plant MH, Saris CJ, Sherman L, Wong LM, Chmait S, Lee MR, Mohr C, Hsieh F, Tasker AS..  (2010)  Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase..  J Med Chem,  53  (7): (2973-2985).  [PMID:20218619] [10.1021/jm100095x]
158. Gangjee A, Namjoshi OA, Ihnat MA, Buchanan A..  (2010)  The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines..  Bioorg Med Chem Lett,  20  (10): (3177-3181).  [PMID:20403693] [10.1016/j.bmcl.2010.03.064]
159. Gangjee A, Kurup S, Ihnat MA, Thorpe JE, Shenoy SS..  (2010)  Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents..  Bioorg Med Chem,  18  (10): (3575-3587).  [PMID:20403700] [10.1016/j.bmc.2010.03.052]
160. Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, Wilsher NE, Martins V, Reynisson J, Atrash B, Faisal A, Urban F, Valenti M, de Haven Brandon A, Box G, Raynaud FI, Workman P, Eccles SA, Bayliss R, Blagg J, Linardopoulos S, McDonald E..  (2010)  Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate..  J Med Chem,  53  (14): (5213-5228).  [PMID:20565112] [10.1021/jm100262j]
161. Yu H, Jung Y, Kim H, Lee J, Oh CH, Yoo KH, Sim T, Hah JM..  (2010)  1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors..  Bioorg Med Chem Lett,  20  (12): (3805-3808).  [PMID:20466542] [10.1016/j.bmcl.2010.04.039]
162. Deng X, Lim SM, Zhang J, Gray NS..  (2010)  Broad spectrum alkynyl inhibitors of T315I Bcr-Abl..  Bioorg Med Chem Lett,  20  (14): (4196-4200).  [PMID:20541934] [10.1016/j.bmcl.2010.05.043]
163. Barile E, De SK, Carlson CB, Chen V, Knutzen C, Riel-Mehan M, Yang L, Dahl R, Chiang G, Pellecchia M..  (2010)  Design, synthesis, and structure-activity relationships of 3-ethynyl-1H-indazoles as inhibitors of the phosphatidylinositol 3-kinase signaling pathway..  J Med Chem,  53  (23): (8368-8375).  [PMID:21062009] [10.1021/jm100825h]
164. Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM..  (2011)  Potent and selective thiophene urea-templated inhibitors of S6K..  Bioorg Med Chem Lett,  21  (2): (849-852).  [PMID:21185721] [10.1016/j.bmcl.2010.11.069]
165. Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, Tóth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I..  (2011)  Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration..  Bioorg Med Chem Lett,  21  (1): (315-319).  [PMID:21112785] [10.1016/j.bmcl.2010.11.010]
166. Kim MH, Kim M, Yu H, Kim H, Yoo KH, Sim T, Hah JM..  (2011)  Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells..  Bioorg Med Chem,  19  (6): (1915-1923).  [PMID:21353571] [10.1016/j.bmc.2011.01.067]
167. Ren X, Duan L, He Q, Zhang Z, Zhou Y, Wu D, Pan J, Pei D, Ding K, Ding K..  (2010)  Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway..  ACS Med Chem Lett,  1  (9): (454-459).  [PMID:24900231] [10.1021/ml100146z]
168. Gould AE, Adams R, Adhikari S, Aertgeerts K, Afroze R, Blackburn C, Calderwood EF, Chau R, Chouitar J, Duffey MO, England DB, Farrer C, Forsyth N, Garcia K, Gaulin J, Greenspan PD, Guo R, Harrison SJ, Huang SC, Iartchouk N, Janowick D, Kim MS, Kulkarni B, Langston SP, Liu JX, Ma LT, Menon S, Mizutani H, Paske E, Renou CC, Rezaei M, Rowland RS, Sintchak MD, Smith MD, Stroud SG, Tregay M, Tian Y, Veiby OP, Vos TJ, Vyskocil S, Williams J, Xu T, Yang JJ, Yano J, Zeng H, Zhang DM, Zhang Q, Galvin KM..  (2011)  Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors..  J Med Chem,  54  (6): (1836-1846).  [PMID:21341678] [10.1021/jm101479y]
169. Peterson EA, Andrews PS, Be X, Boezio AA, Bush TL, Cheng AC, Coats JR, Colletti AE, Copeland KW, DuPont M, Graceffa R, Grubinska B, Harmange JC, Kim JL, Mullady EL, Olivieri P, Schenkel LB, Stanton MK, Teffera Y, Whittington DA, Cai T, La DS..  (2011)  Discovery of triazine-benzimidazoles as selective inhibitors of mTOR..  Bioorg Med Chem Lett,  21  (7): (2064-2070).  [PMID:21376583] [10.1016/j.bmcl.2011.02.007]
170. Charrier JD, Miller A, Kay DP, Brenchley G, Twin HC, Collier PN, Ramaya S, Keily SB, Durrant SJ, Knegtel RM, Tanner AJ, Brown K, Curnock AP, Jimenez JM..  (2011)  Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors..  J Med Chem,  54  (7): (2341-2350).  [PMID:21391610] [10.1021/jm101499u]
171. Okamoto M, Kojima H, Saito N, Okabe T, Masuda Y, Furuya T, Nagano T..  (2011)  Virtual screening and further development of novel ALK inhibitors..  Bioorg Med Chem,  19  (10): (3086-3095).  [PMID:21515061] [10.1016/j.bmc.2011.04.008]
172. Lin WH, Hsieh SY, Yen SC, Chen CT, Yeh TK, Hsu T, Lu CT, Chen CP, Chen CW, Chou LH, Huang YL, Cheng AH, Chang YI, Tseng YJ, Yen KR, Chao YS, Hsu JT, Jiaang WT..  (2011)  Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)..  Bioorg Med Chem,  19  (14): (4173-4182).  [PMID:21708468] [10.1016/j.bmc.2011.06.016]
173. Luan X, Gao C, Zhang N, Chen Y, Sun Q, Tan C, Liu H, Jin Y, Jiang Y..  (2011)  Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors..  Bioorg Med Chem,  19  (11): (3312-3319).  [PMID:21576023] [10.1016/j.bmc.2011.04.053]
174. Ebada SS, Schulz B, Wray V, Totzke F, Kubbutat MH, Müller WE, Hamacher A, Kassack MU, Lin W, Proksch P..  (2011)  Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp..  Bioorg Med Chem,  19  (15): (4644-4651).  [PMID:21741249] [10.1016/j.bmc.2011.06.013]
175. Shi W, Nacev BA, Aftab BT, Head S, Rudin CM, Liu JO..  (2011)  Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling..  J Med Chem,  54  (20): (7363-7374).  [PMID:21936514] [10.1021/jm200944b]
176. Kim H, Kim M, Lee J, Yu H, Hah JM..  (2011)  Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells..  Bioorg Med Chem,  19  (22): (6760-6767).  [PMID:22014755] [10.1016/j.bmc.2011.09.042]
177. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K..  (2011)  Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold..  J Med Chem,  54  (23): (8030-8050).  [PMID:22003817] [10.1021/jm2008634]
178. Tripathy R, McHugh RJ, Ghose AK, Ott GR, Angeles TS, Albom MS, Huang Z, Aimone LD, Cheng M, Dorsey BD..  (2011)  Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group..  Bioorg Med Chem Lett,  21  (24): (7261-7264).  [PMID:22061645] [10.1016/j.bmcl.2011.10.055]
179. Gangjee A, Kurup S, Ihnat MA, Thorpe JE, Disch B..  (2012)  N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors..  Bioorg Med Chem,  20  (2): (910-914).  [PMID:22204741] [10.1016/j.bmc.2011.11.058]
180. Suzuki N, Shiota T, Watanabe F, Haga N, Murashi T, Ohara T, Matsuo K, Omori N, Yari H, Dohi K, Inoue M, Iguchi M, Sentou J, Wada T..  (2012)  Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases..  Bioorg Med Chem Lett,  22  (1): (456-460).  [PMID:22101132] [10.1016/j.bmcl.2011.10.103]
181. Powell NA, Kohrt JT, Filipski KJ, Kaufman M, Sheehan D, Edmunds JE, Delaney A, Wang Y, Bourbonais F, Lee DY, Schwende F, Sun F, McConnell P, Catana C, Chen H, Ohren J, Perrin LA..  (2012)  Novel and selective spiroindoline-based inhibitors of Sky kinase..  Bioorg Med Chem Lett,  22  (1): (190-193).  [PMID:22119469] [10.1016/j.bmcl.2011.11.036]
182. Caruso M, Valsasina B, Ballinari D, Bertrand J, Brasca MG, Caldarelli M, Cappella P, Fiorentini F, Gianellini LM, Scolaro A, Beria I..  (2012)  5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors..  Bioorg Med Chem Lett,  22  (1): (96-101).  [PMID:22154349] [10.1016/j.bmcl.2011.11.065]
183. Bijian K, Zhang Z, Xu B, Jie S, Chen B, Wan S, Wu J, Jiang T, Alaoui-Jamali MA..  (2012)  Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases..  Eur J Med Chem,  48  (143-152).  [PMID:22204902] [10.1016/j.ejmech.2011.12.006]
184. Heidary DK, Huang G, Boucher D, Ma J, Forster C, Grey R, Xu J, Arnost M, Choquette D, Chen G, Zhou JH, Yao YM, Ball ED, Namchuk M, Davies RJ, Henkel G..  (2012)  VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia..  J Med Chem,  55  (2): (725-734).  [PMID:22221201] [10.1021/jm201198w]
185. Gangjee A, Zaware N, Raghavan S, Yang J, Thorpe JE, Ihnat MA..  (2012)  N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation..  Bioorg Med Chem,  20  (7): (2444-2454).  [PMID:22370340] [10.1016/j.bmc.2012.01.029]
186. Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM..  (2012)  Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors..  Bioorg Med Chem Lett,  22  (5): (2015-2019).  [PMID:22335895] [10.1016/j.bmcl.2012.01.028]
187. Norman MH, Liu L, Lee M, Xi N, Fellows I, D'Angelo ND, Dominguez C, Rex K, Bellon SF, Kim TS, Dussault I..  (2012)  Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives..  J Med Chem,  55  (5): (1858-1867).  [PMID:22320343] [10.1021/jm201330u]
188. Li WW, Wang XY, Zheng RL, Yan HX, Cao ZX, Zhong L, Wang ZR, Ji P, Yang LL, Wang LJ, Xu Y, Liu JJ, Yang J, Zhang CH, Ma S, Feng S, Sun QZ, Wei YQ, Yang SY..  (2012)  Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo..  J Med Chem,  55  (8): (3852-3866).  [PMID:22452518] [10.1021/jm300042x]
189. Prabhakaran J, Arango V, Majo VJ, Simpson NR, Kassir SA, Underwood MD, Polavarapu H, Bruce JN, Canoll P, Mann JJ, Kumar JS..  (2012)  Synthesis and in vitro evaluation of [18F](R)-FEPAQ: a potential PET ligand for VEGFR2..  Bioorg Med Chem Lett,  22  (15): (5104-5107).  [PMID:22749281] [10.1016/j.bmcl.2012.05.099]
190. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B..  (2012)  Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α..  J Med Chem,  55  (9): (4407-4424).  [PMID:22533818] [10.1021/jm300309a]
191. Nakano H, Saito N, Parker L, Tada Y, Abe M, Tsuganezawa K, Yokoyama S, Tanaka A, Kojima H, Okabe T, Nagano T..  (2012)  Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound..  J Med Chem,  55  (11): (5151-5164).  [PMID:22540945] [10.1021/jm3001289]
192. Leahy JW, Buhr CA, Johnson HW, Kim BG, Baik T, Cannoy J, Forsyth TP, Jeong JW, Lee MS, Ma S, Noson K, Wang L, Williams M, Nuss JM, Brooks E, Foster P, Goon L, Heald N, Holst C, Jaeger C, Lam S, Lougheed J, Nguyen L, Plonowski A, Song J, Stout T, Wu X, Yakes MF, Yu P, Zhang W, Lamb P, Raeber O..  (2012)  Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors..  J Med Chem,  55  (11): (5467-5482).  [PMID:22548342] [10.1021/jm300403a]
193. Lin X, Huang XP, Chen G, Whaley R, Peng S, Wang Y, Zhang G, Wang SX, Wang S, Roth BL, Huang N..  (2012)  Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors..  J Med Chem,  55  (12): (5749-5759).  [PMID:22694093] [10.1021/jm300338m]
194. Dakshanamurthy S, Issa NT, Assefnia S, Seshasayee A, Peters OJ, Madhavan S, Uren A, Brown ML, Byers SW..  (2012)  Predicting new indications for approved drugs using a proteochemometric method..  J Med Chem,  55  (15): (6832-6848).  [PMID:22780961] [10.1021/jm300576q]
195. Tell V, Holzer M, Herrmann L, Mahmoud KA, Schächtele C, Totzke F, Hilgeroth A..  (2012)  Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases..  Bioorg Med Chem Lett,  22  (22): (6914-6918).  [PMID:23039927] [10.1016/j.bmcl.2012.09.006]
196. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS..  (2012)  GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor..  Bioorg Med Chem Lett,  22  (17): (5625-5629).  [PMID:22863203] [10.1016/j.bmcl.2012.06.104]
197. Amombo GM, Kramer T, Lo Monte F, Göring S, Fach M, Smith S, Kolb S, Schubenel R, Baumann K, Schmidt B..  (2012)  Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3..  Bioorg Med Chem Lett,  22  (24): (7634-7640).  [PMID:23107479] [10.1016/j.bmcl.2012.10.016]
198. Zhang P, Hu HR, Bian SH, Huang ZH, Chu Y, Ye DY..  (2013)  Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β)..  Eur J Med Chem,  61  (95-103).  [PMID:23047001] [10.1016/j.ejmech.2012.09.021]
199. Yang LL, Li GB, Ma S, Zou C, Zhou S, Sun QZ, Cheng C, Chen X, Wang LJ, Feng S, Li LL, Yang SY..  (2013)  Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo..  J Med Chem,  56  (4): (1641-1655).  [PMID:23362959] [10.1021/jm301537p]
200. Gangjee A, Namjoshi OA, Yu J, Ihnat MA, Thorpe JE, Bailey-Downs LC..  (2013)  N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents..  Bioorg Med Chem,  21  (5): (1312-1323).  [PMID:23375090] [10.1016/j.bmc.2012.12.045]
201. Gangjee A, Zaware N, Raghavan S, Disch BC, Thorpe JE, Bastian A, Ihnat MA..  (2013)  Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents..  Bioorg Med Chem,  21  (7): (1857-1864).  [PMID:23434139] [10.1016/j.bmc.2013.01.040]
202. Brown A, Shi Q, Moore TW, Yoon Y, Prussia A, Maddox C, Liotta DC, Shim H, Snyder JP..  (2013)  Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties..  J Med Chem,  56  (9): (3456-3466).  [PMID:23550937] [10.1021/jm4002692]
203. Mortensen DS, Sapienza J, Lee BG, Perrin-Ninkovic SM, Harris R, Shevlin G, Parnes JS, Whitefield B, Hickman M, Khambatta G, Bisonette RR, Peng S, Gamez JC, Leisten J, Narla RK, Fultz KE, Sankar S..  (2013)  Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase..  Bioorg Med Chem Lett,  23  (6): (1588-1591).  [PMID:23414803] [10.1016/j.bmcl.2013.01.110]
204. Perspicace E, Jouan-Hureaux V, Ragno R, Ballante F, Sartini S, La Motta C, Da Settimo F, Chen B, Kirsch G, Schneider S, Faivre B, Hesse S..  (2013)  Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2)..  Eur J Med Chem,  63  (765-781).  [PMID:23583911] [10.1016/j.ejmech.2013.03.022]
205. Sanphanya K, Wattanapitayakul SK, Phowichit S, Fokin VV, Vajragupta O..  (2013)  Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach..  Bioorg Med Chem Lett,  23  (10): (2962-2967).  [PMID:23562241] [10.1016/j.bmcl.2013.03.042]
206. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT..  (2013)  Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)..  Bioorg Med Chem,  21  (11): (2856-2867).  [PMID:23618709] [10.1016/j.bmc.2013.03.083]
207. Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M..  (2013)  Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors..  Bioorg Med Chem Lett,  23  (9): (2743-2749).  [PMID:23522834] [10.1016/j.bmcl.2013.02.065]
208. Li J, Hu H, Lang Q, Zhang H, Huang Q, Wu Y, Yu L..  (2013)  A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity..  Eur J Med Chem,  65  (151-157).  [PMID:23707920] [10.1016/j.ejmech.2013.04.058]
209. Troxler T, Greenidge P, Zimmermann K, Desrayaud S, Drückes P, Schweizer T, Stauffer D, Rovelli G, Shimshek DR..  (2013)  Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2..  Bioorg Med Chem Lett,  23  (14): (4085-4090).  [PMID:23768909] [10.1016/j.bmcl.2013.05.054]
210. MacKinnon CH, Lau K, Burch JD, Chen Y, Dines J, Ding X, Eigenbrot C, Heifetz A, Jaochico A, Johnson A, Kraemer J, Kruger S, Krülle TM, Liimatta M, Ly J, Maghames R, Montalbetti CA, Ortwine DF, Pérez-Fuertes Y, Shia S, Stein DB, Trani G, Vaidya DG, Wang X, Bromidge SM, Wu LC, Pei Z..  (2013)  Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK)..  Bioorg Med Chem Lett,  23  (23): (6331-6335).  [PMID:24138940] [10.1016/j.bmcl.2013.09.069]
211. Matsumoto S, Miyamoto N, Hirayama T, Oki H, Okada K, Tawada M, Iwata H, Nakamura K, Yamasaki S, Miki H, Hori A, Imamura S..  (2013)  Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors..  Bioorg Med Chem,  21  (24): (7686-7698).  [PMID:24216091] [10.1016/j.bmc.2013.10.028]
212. Cheng X, Merz KH, Vatter S, Christ J, Wölfl S, Eisenbrand G..  (2014)  7,7'-Diazaindirubin--a small molecule inhibitor of casein kinase 2 in vitro and in cells..  Bioorg Med Chem,  22  (1): (247-255).  [PMID:24326279] [10.1016/j.bmc.2013.11.031]
213. Sartini S, Coviello V, Bruno A, La Pietra V, Marinelli L, Simorini F, Taliani S, Salerno S, Marini AM, Fioravanti A, Orlandi P, Antonelli A, Da Settimo F, Novellino E, Bocci G, La Motta C..  (2014)  Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, synthesis, functional evaluation, and molecular modeling studies..  J Med Chem,  57  (4): (1225-1235).  [PMID:24447248] [10.1021/jm401358b]
214. El-Nassan HB..  (2014)  Recent progress in the identification of BRAF inhibitors as anti-cancer agents..  Eur J Med Chem,  72  (170-205).  [PMID:24424304] [10.1016/j.ejmech.2013.11.018]
215. Tang Z, Niu S, Liu F, Lao K, Miao J, Ji J, Wang X, Yan M, Zhang L, You Q, Xiao H, Xiang H..  (2014)  Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2..  Bioorg Med Chem Lett,  24  (9): (2129-2133).  [PMID:24721727] [10.1016/j.bmcl.2014.03.042]
216. Gogate PN, Ethirajan M, Kurenova EV, Magis AT, Pandey RK, Cance WG..  (2014)  Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction..  Eur J Med Chem,  80  (154-166).  [PMID:24780592] [10.1016/j.ejmech.2014.04.041]
217. Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, Dean B, Dudley DA, Gould SE, Pacheco P, Shahidi-Latham S, Wang W, West K, Yin J, Moffat J, Schwarz JB..  (2014)  Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2..  Bioorg Med Chem Lett,  24  (12): (2635-2639).  [PMID:24813737] [10.1016/j.bmcl.2014.04.068]
218. Zhang X, Raghavan S, Ihnat M, Thorpe JE, Disch BC, Bastian A, Bailey-Downs LC, Dybdal-Hargreaves NF, Rohena CC, Hamel E, Mooberry SL, Gangjee A..  (2014)  The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents..  Bioorg Med Chem,  22  (14): (3753-3772).  [PMID:24890652] [10.1016/j.bmc.2014.04.049]
219. Göring S, Taymans JM, Baekelandt V, Schmidt B..  (2014)  Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond..  Bioorg Med Chem Lett,  24  (19): (4630-4637).  [PMID:25219901] [10.1016/j.bmcl.2014.08.049]
220. Xie F, Zhu H, Zhang H, Lang Q, Tang L, Huang Q, Yu L..  (2015)  In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel Aurora B kinase inhibitor..  Eur J Med Chem,  89  (310-319).  [PMID:25462247] [10.1016/j.ejmech.2014.10.044]
221. Eldehna WM, Ibrahim HS, Abdel-Aziz HA, Farrag NN, Youssef MM..  (2015)  Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl/benzylphthalazin-1-ones..  Eur J Med Chem,  89  (549-560).  [PMID:25462265] [10.1016/j.ejmech.2014.10.064]
222. Zhang P, Li S, Gao Y, Lu W, Huang K, Ye D, Li X, Chu Y..  (2014)  Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake..  Bioorg Med Chem Lett,  24  (24): (5639-5643).  [PMID:25467150] [10.1016/j.bmcl.2014.10.078]
223. Song Z, Yang Y, Liu Z, Peng X, Guo J, Yang X, Wu K, Ai J, Ding J, Geng M, Zhang A..  (2015)  Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases..  J Med Chem,  58  (1): (197-211).  [PMID:24785465] [10.1021/jm5005144]
224. Horbert R, Pinchuk B, Johannes E, Schlosser J, Schmidt D, Cappel D, Totzke F, Schächtele C, Peifer C..  (2015)  Optimization of potent DFG-in inhibitors of platelet derived growth factor receptorβ (PDGF-Rβ) guided by water thermodynamics..  J Med Chem,  58  (1): (170-182).  [PMID:25007344] [10.1021/jm500373x]
225. Shi L, Wu TT, Wang Z, Xue JY, Xu YG..  (2014)  Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors..  Eur J Med Chem,  84  (698-707).  [PMID:25064347] [10.1016/j.ejmech.2014.07.071]
226. Shi L, Wu TT, Wang Z, Xue JY, Xu YG..  (2014)  Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2..  Bioorg Med Chem,  22  (17): (4735-4744).  [PMID:25082515] [10.1016/j.bmc.2014.07.008]
227. Wang L, Stanley M, Boggs JW, Crawford TD, Bravo BJ, Giannetti AM, Harris SF, Magnuson SR, Nonomiya J, Schmidt S, Wu P, Ye W, Gould SE, Murray LJ, Ndubaku CO, Chen H..  (2014)  Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors..  Bioorg Med Chem Lett,  24  (18): (4546-4552).  [PMID:25139565] [10.1016/j.bmcl.2014.07.071]
228. Muth F, Günther M, Bauer SM, Döring E, Fischer S, Maier J, Drückes P, Köppler J, Trappe J, Rothbauer U, Koch P, Laufer SA..  (2015)  Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases..  J Med Chem,  58  (1): (443-456).  [PMID:25475894] [10.1021/jm501557a]
229. Zhang X, Raghavan S, Ihnat M, Hamel E, Zammiello C, Bastian A, Mooberry SL, Gangjee A..  (2015)  The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents..  Bioorg Med Chem,  23  (10): (2408-2423).  [PMID:25882519] [10.1016/j.bmc.2015.03.061]
230. Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL, Kaiser R..  (2015)  Nintedanib: from discovery to the clinic..  J Med Chem,  58  (3): (1053-1063).  [PMID:25474320] [10.1021/jm501562a]
231. Lawrence HR, Mahajan K, Luo Y, Zhang D, Tindall N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP, Lawrence NJ..  (2015)  Development of novel ACK1/TNK2 inhibitors using a fragment-based approach..  J Med Chem,  58  (6): (2746-2763).  [PMID:25699576] [10.1021/jm501929n]
232. Tintori C, La Sala G, Vignaroli G, Botta L, Fallacara AL, Falchi F, Radi M, Zamperini C, Dreassi E, Dello Iacono L, Orioli D, Biamonti G, Garbelli M, Lossani A, Gasparrini F, Tuccinardi T, Laurenzana I, Angelucci A, Maga G, Schenone S, Brullo C, Musumeci F, Desogus A, Crespan E, Botta M..  (2015)  Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors..  J Med Chem,  58  (11): (4590-4609).  [PMID:25923950] [10.1021/acs.jmedchem.5b00140]
233. Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, Zhang X, Zhang Y, Kays L, Hipskind PA, Wrobleski AD, Lobb KL, Clay JM, Cohen JD, Walgren JL, McCann D, Patel P, Clawson DK, Guo S, Manglicmot D, Groshong C, Logan C, Starling JJ, Flynn DL..  (2015)  Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells..  J Med Chem,  58  (10): (4165-4179).  [PMID:25965804] [10.1021/acs.jmedchem.5b00067]
234. Choi HS, Rucker PV, Wang Z, Fan Y, Albaugh P, Chopiuk G, Gessier F, Sun F, Adrian F, Liu G, Hood T, Li N, Jia Y, Che J, McCormack S, Li A, Li J, Steffy A, Culazzo A, Tompkins C, Phung V, Kreusch A, Lu M, Hu B, Chaudhary A, Prashad M, Tuntland T, Liu B, Harris J, Seidel HM, Loren J, Molteni V..  (2015)  (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors..  ACS Med Chem Lett,  6  (5): (562-567).  [PMID:26005534] [10.1021/acsmedchemlett.5b00050]
235. Eldehna WM, Fares M, Ibrahim HS, Aly MH, Zada S, Ali MM, Abou-Seri SM, Abdel-Aziz HA, Abou El Ella DA..  (2015)  Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking..  Eur J Med Chem,  100  (89-97).  [PMID:26071861] [10.1016/j.ejmech.2015.05.040]
236. Chen CT, Hsu JT, Lin WH, Lu CT, Yen SC, Hsu T, Huang YL, Song JS, Chen CH, Chou LH, Yen KJ, Chen CP, Kuo PC, Huang CL, Liu HE, Chao YS, Yeh TK, Jiaang WT..  (2015)  Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations..  Eur J Med Chem,  100  (151-161).  [PMID:26081023] [10.1016/j.ejmech.2015.05.008]
237. Frett B, McConnell N, Wang Y, Xu Z, Ambrose A, Li HY..  (2014)  Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies..  Medchemcomm,  5  (10): (1507-1514).  [PMID:26843921] [10.1039/c4md00251b]
238. Lin XD, Yang HW, Ma S, Li WW, Zhang CH, Wang WJ, Xiang R, Li LL, Yang SY..  (2015)  Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors..  Bioorg Med Chem Lett,  25  (20): (4534-4538).  [PMID:26342867] [10.1016/j.bmcl.2015.08.068]
239. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L..  (2015)  Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity..  Bioorg Med Chem,  23  (21): (7000-7006).  [PMID:26455654] [10.1016/j.bmc.2015.09.038]
240. Ravez S, Arsenlis S, Barczyk A, Dupont A, Frédérick R, Hesse S, Kirsch G, Depreux P, Goossens L..  (2015)  Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors..  Bioorg Med Chem,  23  (22): (7340-7347).  [PMID:26526740] [10.1016/j.bmc.2015.10.035]
241. Peng FW, Wu TT, Ren ZW, Xue JY, Shi L..  (2015)  Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase..  Bioorg Med Chem Lett,  25  (22): (5137-5141).  [PMID:26475519] [10.1016/j.bmcl.2015.10.006]
242. Elkamhawy A, Farag AK, Viswanath AN, Bedair TM, Leem DG, Lee KT, Pae AN, Roh EJ..  (2015)  Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking..  Bioorg Med Chem Lett,  25  (22): (5147-5154).  [PMID:26475520] [10.1016/j.bmcl.2015.10.003]
243. Nakano H, Hasegawa T, Saito N, Furukawa K, Mukaida N, Kojima H, Okabe T, Nagano T..  (2015)  Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent..  Bioorg Med Chem Lett,  25  (24): (5687-5693).  [PMID:26547690] [10.1016/j.bmcl.2015.10.098]
244. Meredith EL, Mainolfi N, Poor S, Qiu Y, Miranda K, Powers J, Liu D, Ma F, Solovay C, Rao C, Johnson L, Ji N, Artman G, Hardegger L, Hanks S, Shen S, Woolfenden A, Fassbender E, Sivak JM, Zhang Y, Long D, Cepeda R, Liu F, Hosagrahara VP, Lee W, Tarsa P, Anderson K, Elliott J, Jaffee B..  (2015)  Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration..  J Med Chem,  58  (23): (9273-9286).  [PMID:26568411] [10.1021/acs.jmedchem.5b01227]
245. Simon-Szabó L, Kokas M, Greff Z, Boros S, Bánhegyi P, Zsákai L, Szántai-Kis C, Vantus T, Mandl J, Bánhegyi G, Vályi-Nagy I, Őrfi L, Ullrich A, Csala M, Kéri G..  (2016)  Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes..  Bioorg Med Chem Lett,  26  (2): (424-428).  [PMID:26704265] [10.1016/j.bmcl.2015.11.099]
246. Abou-Seri SM, Eldehna WM, Ali MM, Abou El Ella DA..  (2016)  1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation..  Eur J Med Chem,  107  (165-179).  [PMID:26590508] [10.1016/j.ejmech.2015.10.053]
247. Yoon H, Kwak Y, Choi S, Cho H, Kim ND, Sim T..  (2016)  A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants..  J Med Chem,  59  (1): (358-373).  [PMID:26652860] [10.1021/acs.jmedchem.5b01522]
248. Shan Y, Wang C, Zhang L, Wang J, Wang M, Dong Y..  (2016)  Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors..  Bioorg Med Chem,  24  (4): (750-758).  [PMID:26753815] [10.1016/j.bmc.2015.12.038]
249. Zhang HQ, Gong FH, Li CG, Zhang C, Wang YJ, Xu YG, Sun LP..  (2016)  Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors..  Eur J Med Chem,  109  (371-379).  [PMID:26826581] [10.1016/j.ejmech.2015.12.032]
250. Aman W, Lee J, Kim M, Yang S, Jung H, Hah JM..  (2016)  Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation..  Bioorg Med Chem Lett,  26  (4): (1188-1192).  [PMID:26810260] [10.1016/j.bmcl.2016.01.037]
251. Huard K, Gosset JR, Montgomery JI, Gilbert A, Hayward MM, Magee TV, Cabral S, Uccello DP, Bahnck K, Brown J, Purkal J, Gorgoglione M, Lanba A, Futatsugi K, Herr M, Genung NE, Aspnes G, Polivkova J, Garcia-Irizarry CN, Li Q, Canterbury D, Niosi M, Vera NB, Li Z, Khunte B, Siderewicz J, Rolph T, Erion DM..  (2016)  Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family..  J Med Chem,  59  (3): (1165-1175).  [PMID:26734723] [10.1021/acs.jmedchem.5b01752]
252. Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J..  (2016)  8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors..  J Med Chem,  59  (4): (1388-1409).  [PMID:26741168] [10.1021/acs.jmedchem.5b01635]
253. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J..  (2016)  Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore..  Bioorg Med Chem Lett,  26  (5): (1443-1451).  [PMID:26852363] [10.1016/j.bmcl.2016.01.062]
254. Newton R, Bowler KA, Burns EM, Chapman PJ, Fairweather EE, Fritzl SJ, Goldberg KM, Hamilton NM, Holt SV, Hopkins GV, Jones SD, Jordan AM, Lyons AJ, Nikki March H, McDonald NQ, Maguire LA, Mould DP, Purkiss AG, Small HF, Stowell AI, Thomson GJ, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ..  (2016)  The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity..  Eur J Med Chem,  112  (20-32).  [PMID:26874741] [10.1016/j.ejmech.2016.01.039]
255. Jordan AM, Begum H, Fairweather E, Fritzl S, Goldberg K, Hopkins GV, Hamilton NM, Lyons AJ, March HN, Newton R, Small HF, Vishwanath S, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ..  (2016)  Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position..  Bioorg Med Chem Lett,  26  (11): (2724-2729).  [PMID:27086121] [10.1016/j.bmcl.2016.03.100]
256. Fan J, Dai Y, Shao J, Peng X, Wang C, Cao S, Zhao B, Ai J, Geng M, Duan W..  (2016)  Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors..  Bioorg Med Chem Lett,  26  (11): (2594-2599).  [PMID:27117427] [10.1016/j.bmcl.2016.04.028]
257. Cherian J, Nacro K, Poh ZY, Guo S, Jeyaraj DA, Wong YX, Ho M, Yang HY, Joy JK, Kwek ZP, Liu B, Wee JL, Ong EH, Choong ML, Poulsen A, Lee MA, Pendharkar V, Ding LJ, Manoharan V, Chew YS, Sangthongpitag K, Lim S, Ong ST, Hill J, Keller TH..  (2016)  Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells..  J Med Chem,  59  (7): (3063-3078).  [PMID:27011159] [10.1021/acs.jmedchem.5b01712]
258. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A..  (2016)  Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors..  J Med Chem,  59  (8): (3886-3905).  [PMID:27010810] [10.1021/acs.jmedchem.6b00087]
259. Mainolfi N, Powers J, Meredith E, Elliott J, Gunderson KG, Poor S, Liu F, Anderson K..  (2016)  Core Replacements in a Potent Series of VEGFR-2 Inhibitors and Their Impact on Potency, Solubility, and hERG..  ACS Med Chem Lett,  7  (4): (357-362).  [PMID:27096041] [10.1021/acsmedchemlett.6b00018]
260. Mainolfi N, Karki R, Liu F, Anderson K..  (2016)  Evolution of a New Class of VEGFR-2 Inhibitors from Scaffold Morphing and Redesign..  ACS Med Chem Lett,  7  (4): (363-367).  [PMID:27096042] [10.1021/acsmedchemlett.5b00486]
261. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J..  (2016)  Identification of quinones as novel PIM1 kinase inhibitors..  Bioorg Med Chem Lett,  26  (13): (3187-3191).  [PMID:27173800] [10.1016/j.bmcl.2016.04.079]
262. Qiang H, Gu W, Huang D, Shi W, Qiu Q, Dai Y, Huang W, Qian H..  (2016)  Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2..  Bioorg Med Chem,  24  (16): (3353-3358).  [PMID:27068889] [10.1016/j.bmc.2016.03.061]
263. Laufer R, Li SW, Liu Y, Ng G, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Mao G, Plotnikova O, Awrey DE, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW..  (2016)  Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK..  Bioorg Med Chem Lett,  26  (15): (3562-3566).  [PMID:27335255] [10.1016/j.bmcl.2016.06.021]
264. Tang Z, Wu C, Wang T, Lao K, Wang Y, Liu L, Muyaba M, Xu P, He C, Luo G, Qian Z, Niu S, Wang L, Wang Y, Xiao H, You Q, Xiang H..  (2016)  Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents..  Eur J Med Chem,  118  (328-339).  [PMID:27176944] [10.1016/j.ejmech.2016.04.029]
265. Kumar V, Guru SK, Jain SK, Joshi P, Gandhi SG, Bharate SB, Bhushan S, Bharate SS, Vishwakarma RA..  (2016)  A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties..  Bioorg Med Chem Lett,  26  (15): (3457-3463).  [PMID:27363938] [10.1016/j.bmcl.2016.06.046]
266. Kim H, Lee C, Yang JS, Choi S, Park CH, Kang JS, Oh SJ, Yun J, Kim MH, Han G..  (2016)  Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia..  Eur J Med Chem,  120  (74-85).  [PMID:27187860] [10.1016/j.ejmech.2016.05.022]
267. Michailidou M, Giannouli V, Kotsikoris V, Papadodima O, Kontogianni G, Kostakis IK, Lougiakis N, Chatziioannou A, Kolisis FN, Marakos P, Pouli N, Loutrari H..  (2016)  Novel pyrazolopyridine derivatives as potential angiogenesis inhibitors: Synthesis, biological evaluation and transcriptome-based mechanistic analysis..  Eur J Med Chem,  121  (143-157).  [PMID:27240270] [10.1016/j.ejmech.2016.05.035]
268. Chen Y, Zheng Y, Jiang Q, Qin F, Zhang Y, Fu L, He G..  (2017)  Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells..  Eur J Med Chem,  127  (997-1011).  [PMID:27839788] [10.1016/j.ejmech.2016.11.009]
269. Pavana RK, Choudhary S, Bastian A, Ihnat MA, Bai R, Hamel E, Gangjee A..  (2017)  Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents..  Bioorg Med Chem,  25  (2): (545-556).  [PMID:27894589] [10.1016/j.bmc.2016.11.026]
270. Argyros O, Lougiakis N, Kouvari E, Papafotika A, Raptopoulou CP, Psycharis V, Christoforidis S, Pouli N, Marakos P, Tamvakopoulos C..  (2017)  Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity..  Eur J Med Chem,  126  (954-968).  [PMID:28006668] [10.1016/j.ejmech.2016.12.025]
271. Murár M, Dobiaš J, Šramel P, Addová G, Hanquet G, Boháč A..  (2017)  Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands..  Eur J Med Chem,  126  (754-761).  [PMID:27940419] [10.1016/j.ejmech.2016.11.003]
272. Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR..  (2017)  A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore..  Bioorg Med Chem Lett,  27  (3): (406-412).  [PMID:28049589] [10.1016/j.bmcl.2016.12.056]
273. Zaware N, Kisliuk R, Bastian A, Ihnat MA, Gangjee A..  (2017)  Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents..  Bioorg Med Chem Lett,  27  (7): (1602-1607).  [PMID:28258797] [10.1016/j.bmcl.2017.02.018]
274. Hoemann M, Wilson N, Argiriadi M, Banach D, Burchat A, Calderwood D, Clapham B, Cox P, Duignan DB, Konopacki D, Somal G, Vasudevan A..  (2016)  Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors..  Bioorg Med Chem Lett,  26  (22): (5562-5567).  [PMID:27789138] [10.1016/j.bmcl.2016.09.077]
275. Ma F, Liu P, Lei M, Liu J, Wang H, Zhao S, Hu L..  (2017)  Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3)..  Eur J Med Chem,  127  (72-86).  [PMID:28038328] [10.1016/j.ejmech.2016.12.038]
276. Lu Y, Mao F, Li X, Zheng X, Wang M, Xu Q, Zhu J, Li J..  (2017)  Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs)..  J Med Chem,  60  (12): (5099-5119).  [PMID:28541695] [10.1021/acs.jmedchem.7b00468]
277. Zhu W, Chen H, Wang Y, Wang J, Peng X, Chen X, Gao Y, Li C, He Y, Ai J, Geng M, Zheng M, Liu H..  (2017)  Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer..  J Med Chem,  60  (14): (6018-6035).  [PMID:28714692] [10.1021/acs.jmedchem.7b00076]
278. Zhao F, Zhang LD, Hao Y, Chen N, Bai R, Wang YJ, Zhang CC, Li GS, Hao LJ, Shi C, Zhang J, Mao Y, Fan Y, Xia GX, Yu JX, Liu YJ..  (2017)  Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization..  Eur J Med Chem,  134  (147-158).  [PMID:28411455] [10.1016/j.ejmech.2017.03.085]
279. Wagman AS, Boyce RS, Brown SP, Fang E, Goff D, Jansen JM, Le VP, Levine BH, Ng SC, Ni ZJ, Nuss JM, Pfister KB, Ramurthy S, Renhowe PA, Ring DB, Shu W, Subramanian S, Zhou XA, Shafer CM, Harrison SD, Johnson KW, Bussiere DE..  (2017)  Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3..  J Med Chem,  60  (20): (8482-8514).  [PMID:29016121] [10.1021/acs.jmedchem.7b00922]
280. Patel HM, Pawara R, Ansari A, Noolvi M, Surana S..  (2017)  Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle..  Bioorg Med Chem,  25  (10): (2713-2723).  [PMID:28366268] [10.1016/j.bmc.2017.03.039]
281. Mah S, Park JH, Jung HY, Ahn K, Choi S, Tae HS, Jung KH, Rho JK, Lee JC, Hong SS, Hong S..  (2017)  Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design..  J Med Chem,  60  (22): (9205-9221).  [PMID:29091425] [10.1021/acs.jmedchem.7b01039]
282. Zhang Y, Chen Y, Zhang D, Wang L, Lu T, Jiao Y..  (2018)  Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines..  J Med Chem,  61  (1): (140-157).  [PMID:29189002] [10.1021/acs.jmedchem.7b01091]
283. Zhang H, Wu W, Feng C, Liu Z, Bai E, Wang X, Lei M, Cheng H, Feng H, Shi J, Wang J, Zhang Z, Jin T, Chen S, Hu S, Zhu Y..  (2017)  Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants..  Eur J Med Chem,  135  (12-23).  [PMID:28426996] [10.1016/j.ejmech.2017.04.036]
284. Hailat MM, Ebrahim HY, Mohyeldin MM, Goda AA, Siddique AB, El Sayed KA..  (2017)  The tobacco cembranoid (1S,2E,4S,7E,11E)-2,7,11-cembratriene-4,6-diol as a novel angiogenesis inhibitory lead for the control of breast malignancies..  Bioorg Med Chem,  25  (15): (3911-3921).  [PMID:28583806] [10.1016/j.bmc.2017.05.028]
285. Li Y, Guo Q, Zhang C, Huang Z, Wang T, Wang X, Wang X, Xu G, Liu Y, Yang S, Fan Y, Xiang R..  (2017)  Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate..  Bioorg Med Chem Lett,  27  (15): (3231-3237).  [PMID:28651979] [10.1016/j.bmcl.2017.06.041]
286. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N..  (2017)  Discovery of DS79182026: A potent orally active hepcidin production inhibitor..  Bioorg Med Chem Lett,  27  (16): (3716-3722).  [PMID:28705644] [10.1016/j.bmcl.2017.07.004]
287. Wang Y, Zhi Y, Jin Q, Lu S, Lin G, Yuan H, Yang T, Wang Z, Yao C, Ling J, Guo H, Li T, Jin J, Li B, Zhang L, Chen Y, Lu T..  (2018)  Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia..  J Med Chem,  61  (4): (1499-1518).  [PMID:29357250] [10.1021/acs.jmedchem.7b01261]
288. Adams CM, Anderson K, Artman G, Bizec JC, Cepeda R, Elliott J, Fassbender E, Ghosh M, Hanks S, Hardegger LA, Hosagrahara VP, Jaffee B, Jendza K, Ji N, Johnson L, Lee W, Liu D, Liu F, Long D, Ma F, Mainolfi N, Meredith EL, Miranda K, Peng Y, Poor S, Powers J, Qiu Y, Rao C, Shen S, Sivak JM, Solovay C, Tarsa P, Woolfenden A, Zhang C, Zhang Y..  (2018)  The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration..  J Med Chem,  61  (4): (1622-1635).  [PMID:29400470] [10.1021/acs.jmedchem.7b01731]
289. Patel S, Meilandt WJ, Erickson RI, Chen J, Deshmukh G, Estrada AA, Fuji RN, Gibbons P, Gustafson A, Harris SF, Imperio J, Liu W, Liu X, Liu Y, Lyssikatos JP, Ma C, Yin J, Lewcock JW, Siu M..  (2017)  Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease..  J Med Chem,  60  (19): (8083-8102).  [PMID:28929759] [10.1021/acs.jmedchem.7b00843]
290. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N..  (2017)  Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives..  Bioorg Med Chem Lett,  27  (23): (5252-5257).  [PMID:29079471] [10.1016/j.bmcl.2017.10.031]
291. Luo G, Li X, Zhang G, Wu C, Tang Z, Liu L, You Q, Xiang H..  (2017)  Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer..  Eur J Med Chem,  140  (252-273).  [PMID:28942113] [10.1016/j.ejmech.2017.09.015]
292. Kahraman DC, Hanquet G, Jeanmart L, Lanners S, Šramel P, Boháč A, Cetin-Atalay R..  (2017)  Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells..  Medchemcomm,  8  (1): (81-87).  [PMID:30108693] [10.1039/C6MD00392C]
293. Abdullaziz MA, Abdel-Mohsen HT, El Kerdawy AM, Ragab FAF, Ali MM, Abu-Bakr SM, Girgis AS, El Diwani HI..  (2017)  Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors..  Eur J Med Chem,  136  (315-329).  [PMID:28505536] [10.1016/j.ejmech.2017.04.068]
294. Yuan H, Liu Q, Zhang L, Hu S, Chen T, Li H, Chen Y, Xu Y, Lu T..  (2018)  Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors..  Eur J Med Chem,  143  (491-502).  [PMID:29202410] [10.1016/j.ejmech.2017.11.073]
295. Farag AK, Elkamhawy A, Londhe AM, Lee KT, Pae AN, Roh EJ..  (2017)  Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders..  Eur J Med Chem,  141  (657-675).  [PMID:29107425] [10.1016/j.ejmech.2017.10.003]
296. Zhi Y, Li B, Yao C, Li H, Chen P, Bao J, Qin T, Wang Y, Lu T, Lu S..  (2018)  Discovery of the selective and efficacious inhibitors of FLT3 mutations..  Eur J Med Chem,  155  (303-315).  [PMID:29894944] [10.1016/j.ejmech.2018.06.010]
297. Reiersølmoen AC, Han J, Sundby E, Hoff BH..  (2018)  Identification of fused pyrimidines as interleukin 17 secretion inhibitors..  Eur J Med Chem,  155  (562-578).  [PMID:29909341] [10.1016/j.ejmech.2018.06.019]
298. Malínková V, Řezníčková E, Jorda R, Gucký T, Kryštof V..  (2017)  Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1..  Bioorg Med Chem,  25  (24): (6523-6535).  [PMID:29089259] [10.1016/j.bmc.2017.10.032]
299. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W..  (2018)  Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer..  Bioorg Med Chem,  26  (3): (590-602).  [PMID:29289448] [10.1016/j.bmc.2017.12.020]
300. Suebsuwong C, Pinkas DM, Ray SS, Bufton JC, Dai B, Bullock AN, Degterev A, Cuny GD..  (2018)  Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors..  Bioorg Med Chem Lett,  28  (4): (577-583).  [PMID:29409752] [10.1016/j.bmcl.2018.01.044]
301. Myers SH, Temps C, Houston DR, Brunton VG, Unciti-Broceta A..  (2018)  Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening..  J Med Chem,  61  (5): (2104-2110).  [PMID:29466002] [10.1021/acs.jmedchem.7b01605]
302. Zang J, Liang X, Huang Y, Jia Y, Li X, Xu W, Chou CJ, Zhang Y..  (2018)  Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously..  J Med Chem,  61  (12): (5304-5322).  [PMID:29787262] [10.1021/acs.jmedchem.8b00384]
303. Schenck Eidam H, Russell J, Raha K, DeMartino M, Qin D, Guan HA, Zhang Z, Zhen G, Yu H, Wu C, Pan Y, Joberty G, Zinn N, Laquerre S, Robinson S, White A, Giddings A, Mohammadi E, Greenwood-Van Meerveld B, Oliff A, Kumar S, Cheung M..  (2018)  Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS..  ACS Med Chem Lett,  9  (7): (623-628).  [PMID:30034590] [10.1021/acsmedchemlett.8b00035]
304. Cho H, Shin I, Ju E, Choi S, Hur W, Kim H, Hong E, Kim ND, Choi HG, Gray NS, Sim T..  (2018)  First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia..  J Med Chem,  61  (18): (8353-8373).  [PMID:30153003] [10.1021/acs.jmedchem.8b00882]
305. Kettle JG, Anjum R, Barry E, Bhavsar D, Brown C, Boyd S, Campbell A, Goldberg K, Grondine M, Guichard S, Hardy CJ, Hunt T, Jones RDO, Li X, Moleva O, Ogg D, Overman RC, Packer MJ, Pearson S, Schimpl M, Shao W, Smith A, Smith JM, Stead D, Stokes S, Tucker M, Ye Y..  (2018)  Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors..  J Med Chem,  61  (19): (8797-8810).  [PMID:30204441] [10.1021/acs.jmedchem.8b00938]
306. Philip S, Kumarasiri M, Teo T, Yu M, Wang S..  (2018)  Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?.  J Med Chem,  61  (12): (5073-5092).  [PMID:29266937] [10.1021/acs.jmedchem.7b00901]
307. Liu L, Tang Z, Wu C, Li X, Huang A, Lu X, You Q, Xiang H..  (2018)  Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents..  Bioorg Med Chem Lett,  28  (6): (1138-1142).  [PMID:29482944] [10.1016/j.bmcl.2017.12.066]
308. Assadieskandar A, Yu C, Maisonneuve P, Liu X, Chen YC, Prakash GKS, Kurinov I, Sicheri F, Zhang C..  (2018)  Effects of rigidity on the selectivity of protein kinase inhibitors..  Eur J Med Chem,  146  (519-528).  [PMID:29407977] [10.1016/j.ejmech.2018.01.053]
309. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J..  (2018)  Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia..  Eur J Med Chem,  150  (366-384).  [PMID:29544149] [10.1016/j.ejmech.2018.03.003]
310. La Pietra V, Sartini S, Botta L, Antonelli A, Ferrari SM, Fallahi P, Moriconi A, Coviello V, Quattrini L, Ke YY, Hsing-Pang H, Da Settimo F, Novellino E, La Motta C, Marinelli L..  (2018)  Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors..  Eur J Med Chem,  150  (491-505).  [PMID:29549836] [10.1016/j.ejmech.2018.02.080]
311. Luo G, Tang Z, Lao K, Li X, You Q, Xiang H..  (2018)  Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity..  Eur J Med Chem,  150  (783-795).  [PMID:29587221] [10.1016/j.ejmech.2018.03.018]
312. He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG..  (2018)  Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells..  Bioorg Med Chem,  26  (14): (3899-3908).  [PMID:29921474] [10.1016/j.bmc.2018.06.010]
313. Pan Z, Chen Y, Liu J, Jiang Q, Yang S, Guo L, He G..  (2018)  Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy..  Eur J Med Chem,  144  (517-528).  [PMID:29288948] [10.1016/j.ejmech.2017.12.046]
314. Lovering F, Morgan P, Allais C, Aulabaugh A, Brodfuehrer J, Chang J, Coe J, Ding W, Dowty H, Fleming M, Frisbie R, Guzova J, Hepworth D, Jasti J, Kortum S, Kurumbail R, Mohan S, Papaioannou N, Strohbach JW, Vincent F, Lee K, Zapf CW..  (2018)  Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors..  Eur J Med Chem,  145  (606-621).  [PMID:29348070] [10.1016/j.ejmech.2017.12.041]
315. Zhang Y, Lv H, Luo L, Xu Y, Pan Y, Wang Y, Lin H, Xiong J, Guo P, Zhang J, Li X, Ye F..  (2018)  Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer..  Eur J Med Chem,  157  (1300-1325).  [PMID:30195240] [10.1016/j.ejmech.2018.08.031]
316. Song M..  (2017)  Recent developments in small molecule therapies for renal cell carcinoma..  Eur J Med Chem,  142  (383-392).  [PMID:28844802] [10.1016/j.ejmech.2017.08.007]
317. Szabadkai I, Torka R, Garamvölgyi R, Baska F, Gyulavári P, Boros S, Illyés E, Choidas A, Ullrich A, Őrfi L..  (2018)  Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors..  J Med Chem,  61  (14): (6277-6292).  [PMID:29928803] [10.1021/acs.jmedchem.8b00672]
318. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS..  (2017)  Discovery of a potent dual ALK and EGFR T790M inhibitor..  Eur J Med Chem,  136  (497-510).  [PMID:28528303] [10.1016/j.ejmech.2017.04.079]
319. Wang Y, Li L, Fan J, Dai Y, Jiang A, Geng M, Ai J, Duan W..  (2018)  Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors..  J Med Chem,  61  (20): (9085-9104).  [PMID:29522671] [10.1021/acs.jmedchem.7b01843]
320. Degorce SL, Barlaam B, Cadogan E, Dishington A, Ducray R, Glossop SC, Hassall LA, Lach F, Lau A, McGuire TM, Nowak T, Ouvry G, Pike KG, Thomason AG..  (2016)  Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase..  J Med Chem,  59  (13): (6281-6292).  [PMID:27259031] [10.1021/acs.jmedchem.6b00519]
321. May-Dracka TL,Arduini R,Bertolotti-Ciarlet A,Bhisetti G,Brickelmaier M,Cahir-McFarland E,Enyedy I,Fontenot JD,Hesson T,Little K,Lyssikatos J,Marcotte D,McKee T,Murugan P,Patterson T,Peng H,Rushe M,Silvian L,Spilker K,Wu P,Xin Z,Burkly LC.  (2018)  Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity..  Bioorg Med Chem Lett,  28  (10): (1964-1971).  [PMID:29636220] [10.1016/j.bmcl.2018.03.032]
322. Michellys PY,Chen B,Jiang T,Jin Y,Lu W,Marsilje TH,Pei W,Uno T,Zhu X,Wu B,Nguyen TN,Bursulaya B,Lee C,Li N,Kim S,Tuntland T,Liu B,Sun F,Steffy A,Hood T.  (2016)  Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors..  Bioorg Med Chem Lett,  26  (3.0): (1090-1096).  [PMID:26750252] [10.1016/j.bmcl.2015.11.049]
323. Ding X,Stasi LP,Ho MH,Zhao B,Wang H,Long K,Xu Q,Sang Y,Sun C,Hu H,Yu H,Wan Z,Wang L,Edge C,Liu Q,Li Y,Dong K,Guan X,Tattersall FD,Reith AD,Ren F.  (2018)  Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors..  Bioorg Med Chem Lett,  28  (9.0): (1615-1620).  [PMID:29588215] [10.1016/j.bmcl.2018.03.045]
324. Zhang CH,Chen K,Jiao Y,Li LL,Li YP,Zhang RJ,Zheng MW,Zhong L,Huang SZ,Song CL,Lin WT,Yang J,Xiang R,Peng B,Han JH,Lu GW,Wei YQ,Yang SY.  (2016)  From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer..  J Med Chem,  59  (21.0): (9788-9805).  [PMID:27739679] [10.1021/acs.jmedchem.6b00943]
325. Yang J,Chen K,Zhang G,Yang QY,Li YS,Huang SZ,Wang YL,Yang W,Jiang XJ,Yan HX,Zhu JQ,Xiang R,Luo YF,Li WM,Wei YQ,Li LL,Yang SY.  (2018)  Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants..  Eur J Med Chem,  143  (1148-1164).  [PMID:29133048] [10.1016/j.ejmech.2017.09.018]
326. Terman, B I BI and 6 more authors..  (1992)  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor..  Biochemical and biophysical research communications,    (30):   [PMID:1417831]
327. Terman, B I BI and 5 more authors..  (1991)  Identification of a new endothelial cell growth factor receptor tyrosine kinase..  Oncogene,      [PMID:1656371]
328. Patterson, C C and 5 more authors..  (1995)  Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor..  The Journal of biological chemistry,    (29):   [PMID:7559454]
329. Waltenberger, J J, Claesson-Welsh, L L, Siegbahn, A A, Shibuya, M M and Heldin, C H CH..  (1994)  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor..  The Journal of biological chemistry,    (28):   [PMID:7929439]
330. Gerber, H P HP and 6 more authors..  (1998)  Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation..  The Journal of biological chemistry,    (13):   [PMID:9804796]
331. Kroll, J J and Waltenberger, J J..  (1998)  VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR)..  Biochemical and biophysical research communications,    (27):   [PMID:9837777]
332. Kendall, R L RL and 5 more authors..  (1999)  Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues..  The Journal of biological chemistry,    (5):   [PMID:10037737]
333. Dougher, M M and Terman, B I BI..  (1999)  Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization..  Oncogene,    (25):   [PMID:10102632]
334. Mitola, S S and 7 more authors..  (2000)  Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells..  Journal of virology,      [PMID:10590123]
335. Kroll, J J and Waltenberger, J J..  (1999)  A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells..  Biochemical and biophysical research communications,    (30):   [PMID:10600473]
336. Takahashi, T T, Yamaguchi, S S, Chida, K K and Shibuya, M M..  (2001)  A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells..  The EMBO journal,    (1):   [PMID:11387210]
337. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ..  (2002)  TTD: Therapeutic Target Database..  Nucleic acids research,    (1):   [PMID:11752352]
338. Walter, Jeffrey W JW and 7 more authors..  (2002)  Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma..  Genes, chromosomes & cancer,      [PMID:11807987]
339. Duval, Martine M, Bédard-Goulet, Sara S, Delisle, Chantal C and Gratton, Jean-Philippe JP..  (2003)  Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination. Consequences on nitric oxide production from endothelial cells..  The Journal of biological chemistry,    (30):   [PMID:12649282]
340. Schueneman, Aaron J AJ and 7 more authors..  (2003)  SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models..  Cancer research,    (15):   [PMID:12873999]
341. Dixelius, Johan J and 6 more authors..  (2003)  Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites..  The Journal of biological chemistry,    (17):   [PMID:12881528]
342. Fox, Stephen B SB and 8 more authors..  (2004)  Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus..  The Journal of pathology,      [PMID:14991896]
343. Holmqvist, Kristina K and 7 more authors..  (2004)  The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration..  The Journal of biological chemistry,    (21):   [PMID:15026417]
344. Jia, Haiyan H and 5 more authors..  (2004)  Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells..  The Journal of biological chemistry,    (20):   [PMID:15215251]
345. Hillier, Ladeana W LW and 121 more authors..  (2005)  Generation and annotation of the DNA sequences of human chromosomes 2 and 4..  Nature,    (7):   [PMID:15815621]
346. Matsumoto, Taro T and 15 more authors..  (2005)  VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis..  The EMBO journal,    (6):   [PMID:15962004]
347. Schöffski, P P and 8 more authors..  (2006)  Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review..  Annals of oncology : official journal of the European Society for Medical Oncology,      [PMID:16418310]
348. Veronese, Maria Luisa ML and 6 more authors..  (2006)  Mechanisms of hypertension associated with BAY 43-9006..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology,    (20):   [PMID:16446323]
349. and Rini, Brian I BI..  (2006)  Sorafenib..  Expert opinion on pharmacotherapy,      [PMID:16503817]
350. Amino, Nobuaki N and 10 more authors..  (2006)  YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors..  Clinical cancer research : an official journal of the American Association for Cancer Research,    (1):   [PMID:16533791]
351. Adnane, Lila L, Trail, Pamela A PA, Taylor, Ian I and Wilhelm, Scott M SM..  (2006)  Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature..  Methods in enzymology,      [PMID:16757355]
352. Lacouture, M E ME and 6 more authors..  (2006)  Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor..  Clinical and experimental dermatology,      [PMID:16824050]
353. Sjöblom, Tobias T and 28 more authors..  (2006)  The consensus coding sequences of human breast and colorectal cancers..  Science (New York, N.Y.),    (13):   [PMID:16959974]
354. Lamalice, Laurent L, Houle, François F and Huot, Jacques J..  (2006)  Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF..  The Journal of biological chemistry,    (10):   [PMID:16966330]
355. Millward, M J MJ and 11 more authors..  (2006)  The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study..  British journal of cancer,    (9):   [PMID:16969355]
356. Fury, Matthew G MG and 9 more authors..  (2007)  A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers..  Investigational new drugs,      [PMID:16983506]
357. and Shibuya, Masabumi M..  (2006)  Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis..  Journal of biochemistry and molecular biology,    (30):   [PMID:17002866]
358. Sonpavde, Guru G and Hutson, Thomas E TE..  (2007)  Pazopanib: a novel multitargeted tyrosine kinase inhibitor..  Current oncology reports,      [PMID:17288876]
359. Yamamoto, Aisaku A and 5 more authors..  (2007)  Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity..  The Journal of dermatology,      [PMID:17584317]
360. Matsui, Junji J and 7 more authors..  (2008)  E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition..  International journal of cancer,    (1):   [PMID:17943726]
361. Cohen, Ezra E W and 13 more authors..  (2008)  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology,    (10):   [PMID:18541897]
362. Jin, Pei P and 9 more authors..  (2008)  Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis..  Arthritis research & therapy,      [PMID:18593464]
363. Jinnin, Masatoshi M and 9 more authors..  (2008)  Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma..  Nature medicine,      [PMID:18931684]
364. Chabot, Catherine C, Spring, Kathleen K, Gratton, Jean-Philippe JP, Elchebly, Mounib M and Royal, Isabelle I..  (2009)  New role for the protein tyrosine phosphatase DEP-1 in Akt activation and endothelial cell survival..  Molecular and cellular biology,      [PMID:18936167]
365. Zhang, Haifeng H and 11 more authors..  (2008)  AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and inflammatory angiogenesis in mice..  The Journal of clinical investigation,      [PMID:19033661]
366. Mellberg, Sofie S and 10 more authors..  (2009)  Transcriptional profiling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis..  FASEB journal : official publication of the Federation of American Societies for Experimental Biology,      [PMID:19136612]
367. Sardon, Teresa T, Cottin, Thomas T, Xu, Jing J, Giannis, Athanassios A and Vernos, Isabelle I..  (2009)  Development and biological evaluation of a novel aurora A kinase inhibitor..  Chembiochem : a European journal of chemical biology,    (13):   [PMID:19199284]
368. Lohela, Marja M, Bry, Maija M, Tammela, Tuomas T and Alitalo, Kari K..  (2009)  VEGFs and receptors involved in angiogenesis versus lymphangiogenesis..  Current opinion in cell biology,      [PMID:19230644]
369. Albuquerque, Romulo J C RJ and 23 more authors..  (2009)  Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth..  Nature medicine,      [PMID:19668192]
370. Zhang, Z Z, Neiva, K G KG, Lingen, M W MW, Ellis, L M LM and Nör, J E JE..  (2010)  VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2..  Cell death and differentiation,      [PMID:19834490]
371. Hao, Jijun and 8 more authors..  (2010)  In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors..  ACS chemical biology,    (19):   [PMID:20020776]
372. Yang, Yan Y, Xie, Peng P, Opatowsky, Yarden Y and Schlessinger, Joseph J..  (2010)  Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling..  Proceedings of the National Academy of Sciences of the United States of America,    (2):   [PMID:20080685]
373. Leppänen, Veli-Matti VM and 9 more authors..  (2010)  Structural determinants of growth factor binding and specificity by VEGF receptor 2..  Proceedings of the National Academy of Sciences of the United States of America,    (9):   [PMID:20145116]
374. Becker, Jürgen J and 7 more authors..  (2010)  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2..  Clinical cancer research : an official journal of the American Association for Cancer Research,    (1):   [PMID:20179233]
375. Garofalo, Antonio A and 5 more authors..  (2010)  Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer..  Journal of enzyme inhibition and medicinal chemistry,      [PMID:20222760]
376. Guo, Shanchun S, Colbert, Laronna S LS, Fuller, Miles M, Zhang, Yuanyuan Y and Gonzalez-Perez, Ruben R RR..  (2010)  Vascular endothelial growth factor receptor-2 in breast cancer..  Biochimica et biophysica acta,      [PMID:20462514]
377. Rigbolt, Kristoffer T G KT and 9 more authors..  (2011)  System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation..  Science signaling,    (15):   [PMID:21406692]
378. Jopling, Helen M HM, Howell, Gareth J GJ, Gamper, Nikita N and Ponnambalam, Sreenivasan S..  (2011)  The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma membrane recycling..  Biochemical and biophysical research communications,    (1):   [PMID:21539813]
379. Kurzrock, Razelle R and 17 more authors..  (2011)  Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology,    (1):   [PMID:21606412]
380. Franklin, Matthew C MC and 11 more authors..  (2011)  The structural basis for the function of two anti-VEGF receptor 2 antibodies..  Structure (London, England : 1993),    (10):   [PMID:21827946]
381. Rho, Seung Bae SB and 5 more authors..  (2012)  Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2..  Cellular signalling,      [PMID:21893193]
382. Zeng, Lingfang L and 14 more authors..  (2013)  Vascular endothelial cell growth-activated XBP1 splicing in endothelial cells is crucial for angiogenesis..  Circulation,    (23):   [PMID:23529610]
383. Urich, Robert R and 8 more authors..  (2013)  De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments..  ACS chemical biology,    (17):   [PMID:23534475]
384. Srinivasan, Srimathi S, Meyer, Rosana D RD, Lugo, Ricardo R and Rahimi, Nader N..  (2013)  Identification of PDCL3 as a novel chaperone protein involved in the generation of functional VEGF receptor 2..  The Journal of biological chemistry,    (9):   [PMID:23792958]
385. Lin, Changsheng C and 8 more authors..  (2014)  Structural basis for activation of trimeric Gi proteins by multiple growth factor receptors via GIV/Girdin..  Molecular biology of the cell,    (5):   [PMID:25187647]
386. Khayati, Farah F and 13 more authors..  (2015)  EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF..  Oncotarget,      [PMID:25825981]
387. Srinivasan, Srimathi S and 11 more authors..  (2015)  Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis..  Angiogenesis,      [PMID:26059764]
388. Qi, Wei W and 39 more authors..  (2017)  An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED..  Nature chemical biology,      [PMID:28135235]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.